<html class="js no-applicationcache geolocation history svg postmessage websockets localstorage sessionstorage websqldatabase webworkers hashchange audio canvas canvastext video webgl cssgradients multiplebgs opacity rgba inlinesvg hsla supports svgclippaths smil fontface generatedcontent textshadow cssanimations backgroundsize borderimage borderradius boxshadow csscolumns csscolumns-width csscolumns-span csscolumns-fill csscolumns-gap csscolumns-rule csscolumns-rulecolor csscolumns-rulestyle csscolumns-rulewidth csscolumns-breakbefore csscolumns-breakafter csscolumns-breakinside flexbox cssreflections csstransforms csstransforms3d csstransitions indexeddb indexeddb-deletedatabase" lang="en" page-id="{9702A835-EC23-468D-9801-946633FA846C}"><!--<![endif]--><head prefix="">
    
<link rel="preconnect" src="https://consent.cookiebot.com/" crossorigin="">
<link rel="dns-prefetch" src="https://consent.cookiebot.com/">
<link rel="preconnect" src="https://connect.facebook.net/" crossorigin="">
<link rel="dns-prefetch" src="https://connect.facebook.net/">
<link rel="preconnect" src="https://www.google-analytics.com/" crossorigin="">
<link rel="dns-prefetch" src="https://www.google-analytics.com/">
<link rel="preconnect" src="https://www.googletagmanager.com/" crossorigin="">
<link rel="dns-prefetch" src="https://www.googletagmanager.com/">
<link rel="preconnect" src="https://players.brightcove.net/" crossorigin="">
<link rel="dns-prefetch" src="https://players.brightcove.net/">
<link rel="preconnect" src="https://vjs.zencdn.net/" crossorigin="">
<link rel="dns-prefetch" src="https://vjs.zencdn.net/">
    



    


        <script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-52SVMWC&amp;l=dataLayer"></script><script type="text/javascript" charset="UTF-8" async="" src="https://consentcdn.cookiebot.com/consentconfig/3c04f870-41c9-42bc-965e-776f1eef473a/state.js"></script><script type="text/javascript" charset="UTF-8" async="" src="https://consent.cookiebot.com/logconsent.ashx?action=accept&amp;nocache=1661205179387&amp;referer=https%3A%2F%2Fwww.amgenpipeline.com%2F&amp;dnt=false&amp;method=strict&amp;clp=true&amp;cls=true&amp;clm=true&amp;cbid=3c04f870-41c9-42bc-965e-776f1eef473a&amp;cbt=optinout&amp;hasdata=true"></script><script type="text/javascript" async="" src="https://www.google-analytics.com/analytics.js"></script><script type="text/javascript" async="" src="https://www.googletagmanager.com/gtag/js?id=G-RGV3CHT3ND&amp;l=dataLayer&amp;cx=c"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-M4CP89H"></script><script type="text/javascript" charset="UTF-8" async="" src="https://consent.cookiebot.com/3c04f870-41c9-42bc-965e-776f1eef473a/cc.js?renew=false&amp;referer=www.amgenpipeline.com&amp;dnt=false&amp;init=false"></script><script id="Cookiebot" src="https://consent.cookiebot.com/uc.js" data-cbid="3c04f870-41c9-42bc-965e-776f1eef473a" type="text/javascript" data-consentmode="disabled" async=""></script>


    
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
        <meta http-equiv="Content-Security-Policy" content="upgrade-insecure-requests">
    <link href="/-/media/Feature/Experience-Accelerator/Bootstrap-4/Bootstrap-4/Styles/bootstrap-grid.css" rel="stylesheet"><link href="/-/media/Base-Themes/Core-Libraries/styles/mediaelementplayer.css" rel="stylesheet"><link href="/-/media/Base-Themes/Core-Libraries/styles/mediaelementplayer-legacy.css" rel="stylesheet"><link href="/-/media/Base-Themes/Core-Libraries/styles/font-awesomemin.css" rel="stylesheet"><link href="/-/media/Base-Themes/Core-Libraries/styles/fullcalendar.css" rel="stylesheet"><link href="/-/media/Base-Themes/Core-Libraries/styles/jquerymCustomScrollbar.css" rel="stylesheet"><link href="/-/media/Base-Themes/Core-Libraries/styles/jquery-ui.css" rel="stylesheet"><link href="/-/media/Base-Themes/Main-Theme/styles/author.css" rel="stylesheet"><link href="/-/media/Base-Themes/Main-Theme/styles/core.css" rel="stylesheet"><link href="/-/media/Base-Themes/Main-Theme/styles/file-type-icons.css" rel="stylesheet"><link href="/-/media/Base-Themes/Main-Theme/styles/grayscale-mode.css" rel="stylesheet"><link href="/-/media/Base-Themes/Main-Theme/styles/reset.css" rel="stylesheet"><link href="/-/media/Themes/Global/Global/Global/styles/ccpa.css" rel="stylesheet"><link href="/-/media/Themes/Global/Global/Global/styles/global-styles.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/google-font.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/comboTreePlugin.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-column-splitter.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-container.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-divider.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-field-editor.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-flash.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-flip.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-forms.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-fullcalendar.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-iframe.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-image.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-language-selector.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-link.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-link-list.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-media-link.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-navigation.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-page-list.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-promo.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-richtext-content.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-site-selector.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-tabs.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/component-title.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/main.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/overlay.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/privacy-warning.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/styles.css" rel="stylesheet"><link href="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/styles/pipeline.css" rel="stylesheet">    
<meta name="VIcurrentDateTime" content="637968019399263553">
<meta name="VirtualFolder" content="/">
<script type="text/javascript" src="/layouts/system/VisitorIdentification.js"></script>

    



<!--Header Media Start-->
            <script src="-/media/Foundation/Amgen/JS/jquery-331min.js"></script>
            <script src="-/media/Foundation/Amgen/JS/comboTreePlugin.js"></script>
            <script src="-/media/Foundation/Amgen/JS/icontains.js"></script>
<!--Header Media End-->




























   
    


    <title>Amgen Pipeline</title>





        <link href="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/amgen-pipeline.png" rel="shortcut icon">


<meta content="A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible." property="og:description"><meta content="http://www.amgenpipeline.com/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Desktop/Pipeline/HeroImage5.jpg" property="og:image"><meta content="Amgen Pipeline" property="og:title"><meta content="https://www.amgenpipeline.com" property="og:url">


<meta content="A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used whenever possible to strengthen the evidence base for as many of our programs as possible." name="description">


<meta content="Amgen Pipeline" name="twitter:title"><meta content="summary_large_image" name="twitter:card">


    <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no">

    



            <script>dataLayer = [{'pageType':'Home','pageCategory':'Amgen Pipeline'}];</script>
        <!-- Google Tag Manager -->
        <script>
            (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
            new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
            j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
            'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
            })(window, document, 'script', 'dataLayer', 'GTM-M4CP89H');
        </script>
        <!-- End Google Tag Manager -->

    
   
<style type="text/css" id="CookiebotDialogStyle">#CybotCookiebotDialog{clip:auto;text-rendering:geometricPrecision;animation:none;animation-delay:0;animation-direction:normal;animation-duration:0;animation-fill-mode:none;animation-iteration-count:1;animation-name:none;animation-play-state:running;animation-timing-function:ease;backface-visibility:visible;background:0;background-attachment:scroll;background-clip:border-box;background-color:transparent;background-color:#ffffff;background-image:none;background-origin:padding-box;background-position:0 0;background-position-x:0;background-position-y:0;background-repeat:repeat;background-size:auto auto;border:0;border-bottom-left-radius:0;border-bottom-right-radius:0;border-collapse:separate;border-image:none;border-radius:0;border-spacing:0;border-top-color:inherit;border-top-left-radius:0;border-top-right-radius:0;border-top-style:none;border-top-width:medium;bottom:auto;box-shadow:none;box-shadow:2px 2px 14px 2px #121212;caption-side:top;clear:none;color:inherit;color:#686666;column-fill:balance;column-gap:normal;column-rule:medium none currentColor;column-rule-color:currentColor;column-rule-style:none;column-rule-width:none;column-span:1;columns:auto;content:normal;counter-increment:none;counter-reset:none;cursor:auto;display:inline;empty-cells:show;filter:Alpha(opacity=100);float:none;font:normal;font-family:inherit;font-family:Segoe UI,Arial,Helvetica,Verdana,sans-serif;font-size:medium;font-size:8pt;font-style:normal;font-variant:normal;font-weight:400;height:auto;hyphens:none;left:auto;left:0;letter-spacing:normal;line-height:normal;line-height:1.231;list-style:none;list-style-image:none;list-style-position:outside;list-style-type:disc;margin:0;max-height:none;max-width:none;min-height:0;min-width:0;opacity:1;orphans:0;outline:0;outline-color:invert;outline-style:none;outline-width:medium;overflow:visible;overflow-x:visible;overflow-y:visible;padding:0 0 8px;page-break-after:auto;page-break-before:auto;page-break-inside:auto;perspective:none;perspective-origin:50% 50%;position:static;position:fixed;right:auto;tab-size:8;table-layout:auto;text-align:inherit;text-align:left;text-align-last:auto;text-decoration:none;text-decoration-color:inherit;text-decoration-line:none;text-decoration-style:solid;text-indent:0;text-shadow:none;text-transform:none;top:auto;top:-800px;transform:none;transform-style:flat;transition:none;transition-delay:0s;transition-duration:0s;transition-property:none;transition-timing-function:ease;vertical-align:baseline;visibility:visible;white-space:normal;widows:0;width:auto;width:100%;word-spacing:normal;z-index:auto;z-index:2147483645}#CybotCookiebotDialog,#CybotCookiebotDialog :after,#CybotCookiebotDialog :before,#CybotCookiebotDialog:after,#CybotCookiebotDialog:before,#CybotCookiebotDialogBody *,#CybotCookiebotDialogDetail *{box-sizing:content-box}#CybotCookiebotDialog[dir=rtl]{text-align:right}#CybotCookiebotDialog a{font-family:Segoe UI,Arial,Helvetica,Verdana,sans-serif;line-height:1.231}#CybotCookiebotDialog a,#CybotCookiebotDialog a:hover{color:#686666;text-decoration:underline}#CybotCookiebotDialog div{font-family:Segoe UI,Arial,Helvetica,Verdana,sans-serif;line-height:1.231}#CybotCookiebotDialog br,#CybotCookiebotDialog td{line-height:1.231}#CybotCookiebotDialogDetailBodyContentCookieContainerAdvertising,#CybotCookiebotDialogDetailBodyContentCookieContainerNecessary,#CybotCookiebotDialogDetailBodyContentCookieContainerPreference,#CybotCookiebotDialogDetailBodyContentCookieContainerStatistics,#CybotCookiebotDialogDetailBodyContentCookieContainerUnclassified{margin:0}#CybotCookiebotDialogPoweredbyLink{height:36px;margin-left:6px;margin-right:0;margin-top:12px;position:absolute;width:48px;z-index:2147483646}div[dir=rtl] #CybotCookiebotDialogPoweredbyLink{margin-left:0;margin-right:6px}#CybotCookiebotDialogPoweredbyImage{border:none;margin:2px 0 0 3px;padding:0;width:46px}#CybotCookiebotDialogBody{margin-left:auto;margin-right:auto;max-width:640px;overflow:hidden;padding-left:0;padding-right:8px;vertical-align:top}div[dir=rtl] #CybotCookiebotDialogBody{padding-left:8px;padding-right:0}#CybotCookiebotDialogBodyContent{font-size:9.5pt;font-weight:400;line-height:130%;min-height:32px;padding:12px 0 8px 80px}div[dir=rtl] #CybotCookiebotDialogBodyContent{padding-left:0;padding-right:80px}#CybotCookiebotDialogBodyContentControls{font-family:Segoe UI,Arial,Helvetica,Verdana,sans-serif;font-size:9.5pt;font-weight:400;line-height:130%;min-height:10px;padding:12px 0 8px 80px}div[dir=rtl] #CybotCookiebotDialogBodyContentControls{padding-left:0;padding-right:80px}.CybotCookiebotDialogBodyContentControlsWrapper{display:inline-block;line-height:16px;margin-left:0;margin-right:14px;position:relative}div[dir=rtl] .CybotCookiebotDialogBodyContentControlsWrapper{margin-left:14px;margin-right:0}#CybotCookiebotDialogBodyContentTitle{color:#686666;display:block;float:none;font-family:Segoe UI,Arial,Helvetica,Verdana,sans-serif;font-size:12pt;font-weight:700;letter-spacing:normal;line-height:100%;margin:2px 0 6px;padding:0;position:static;text-align:left;visibility:visible}div[dir=rtl] #CybotCookiebotDialogBodyContentTitle{text-align:right}#CybotCookiebotDialogBodyContentText{text-align:left}#CybotCookiebotDialogBodyContentText ul{display:block;list-style-type:disc;margin:1em 0 1.25em;padding:0 0 0 40px}#CybotCookiebotDialogBodyContentText ul li{display:list-item;list-style-type:disc;margin:0;padding:0}div[dir=rtl] #CybotCookiebotDialogBodyContentText{text-align:right}#CybotCookiebotDialogBodyButtons{display:block;margin:0 0 6px 6px;padding-left:63px;padding-right:0;z-index:10}div[dir=rtl] #CybotCookiebotDialogBodyButtons{margin:0 6px 6px 0;padding-left:0;padding-right:63px}#CybotCookiebotDialogBodyButtons a,#CybotCookiebotDialogBodyButtons a:hover{color:#ffffff;text-decoration:none}.CybotCookiebotDialogBodyButton{box-sizing:content-box;display:inline-block;font-size:9.5pt;font-weight:600;margin-left:12px;margin-right:0;margin-top:8px;min-width:80px;padding:2px 4px;text-align:center;white-space:nowrap;z-index:10}.CybotCookiebotDialogBodyButton:after,.CybotCookiebotDialogBodyButton:before{box-sizing:content-box}div[dir=rtl] .CybotCookiebotDialogBodyButton{margin-left:0;margin-right:12px}#CybotCookiebotDialogBodyButtonAccept{background-color:#006aa3;border:1px solid #006aa3}#CybotCookiebotDialogBodyButtonDecline{background-color:#b4b0b0;border:1px solid #b4b0b0}#CybotCookiebotDialogBodyButtons .CybotCookiebotDialogBodyLink,#CybotCookiebotDialogBodyLevelDetailsButton{background-image:url(data:image/png;base64,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);background-position:right 12px;background-position-x:right;background-position-y:12px;background-repeat:no-repeat;border-left:0;border-right:5px solid transparent;color:#686666;display:inline-block;font-size:9pt;margin-top:8px;padding:7px 19px 0 0;text-align:right;text-decoration:none}div[dir=rtl] #CybotCookiebotDialogBodyButtons .CybotCookiebotDialogBodyLink,div[dir=rtl] #CybotCookiebotDialogBodyLevelDetailsButton{background-position:left 12px;background-position-x:left;background-position-y:12px;border-left:5px solid transparent;border-right:0;padding-left:19px;padding-right:0}div[dir=rtl] #CybotCookiebotDialogBodyLevelDetailsButton{background-position:left 5px!important;background-position-x:left!important;background-position-y:5px!important}#CybotCookiebotDialogBodyButtons .CybotCookiebotDialogBodyLink:hover,#CybotCookiebotDialogBodyLevelDetailsButton:hover{color:#686666;text-decoration:underline}.CybotCookiebotDialogBodyLevelDetailsButtonExpanded,.CybotCookiebotDialogBodyLinkExpanded{background-image:url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAkAAAAGCAYAAAARx7TFAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJbWFnZVJlYWR5ccllPAAAAyBpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdpbj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+IDx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDUuMC1jMDYwIDYxLjEzNDc3NywgMjAxMC8wMi8xMi0xNzozMjowMCAgICAgICAgIj4gPHJkZjpSREYgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj4gPHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9IiIgeG1sbnM6eG1wPSJodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvIiB4bWxuczp4bXBNTT0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wL21tLyIgeG1sbnM6c3RSZWY9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC9zVHlwZS9SZXNvdXJjZVJlZiMiIHhtcDpDcmVhdG9yVG9vbD0iQWRvYmUgUGhvdG9zaG9wIENTNSBXaW5kb3dzIiB4bXBNTTpJbnN0YW5jZUlEPSJ4bXAuaWlkOjU0QzAwODExNzk0MjExRTQ4QzBERTBGMTkxMUY2M0M0IiB4bXBNTTpEb2N1bWVudElEPSJ4bXAuZGlkOjU0QzAwODEyNzk0MjExRTQ4QzBERTBGMTkxMUY2M0M0Ij4gPHhtcE1NOkRlcml2ZWRGcm9tIHN0UmVmOmluc3RhbmNlSUQ9InhtcC5paWQ6NTRDMDA4MEY3OTQyMTFFNDhDMERFMEYxOTExRjYzQzQiIHN0UmVmOmRvY3VtZW50SUQ9InhtcC5kaWQ6NTRDMDA4MTA3OTQyMTFFNDhDMERFMEYxOTExRjYzQzQiLz4gPC9yZGY6RGVzY3JpcHRpb24+IDwvcmRmOlJERj4gPC94OnhtcG1ldGE+IDw/eHBhY2tldCBlbmQ9InIiPz576KdnAAAATklEQVR42kyO2xEAMQgCJZ3afxFcyGRz+uMD3EHdXbYrJSltrz4Dt4UBNfsWPG614oRwO2Q/Eg+IwvnDj8kjk+48MzmZeNYI/4jRPwEGAFy/MS7NcXxJAAAAAElFTkSuQmCC)!important}div[dir=rtl] .CybotCookiebotDialogBodyLevelDetailsButtonExpanded{background-position:left 5px!important;background-position-x:left!important;background-position-y:5px!important}a#CybotCookiebotDialogBodyLevelDetailsButton{background-position:right 5px;background-position-x:right;background-position-y:5px;color:#686666;line-height:16px;margin:1px 0 0;padding-left:4px;padding-top:0;text-align:left;text-decoration:none}div[dir=rtl] a#CybotCookiebotDialogBodyLevelDetailsButton{text-align:right}a#CybotCookiebotDialogBodyLevelDetailsButton:hover{color:#686666;text-decoration:none}#CybotCookiebotDialogBodyButtonDetails{display:inline-block;float:right;outline:none}div[dir=rtl] #CybotCookiebotDialogBodyButtonDetails{float:left}#CybotCookiebotDialogBodyButtonDetails:focus,#CybotCookiebotDialogBodyLevelDetailsButton:focus{text-decoration:underline}#CybotCookiebotDialogBodyLevelWrapper{display:none;pointer-events:none;text-align:right}div[dir=rtl] #CybotCookiebotDialogBodyLevelWrapper{text-align:left}#CybotCookiebotDialogBodyLevelButtons{float:left;font-size:9pt;margin-left:8px;margin-right:0;pointer-events:auto}div[dir=rtl] #CybotCookiebotDialogBodyLevelButtons{float:right;margin-left:0;margin-right:8px}#CybotCookiebotDialogBodyLevelButtonsTable{display:inline-table;margin:5px 0}div[dir=rtl] #CybotCookiebotDialogBodyLevelButtonsTable{margin-left:16px;margin-right:0}#CybotCookiebotDialogBodyLevelButtonsRow{display:table-row}#CybotCookiebotDialogBodyLevelButtonsSelectPane{border:1px solid #ffffff;-webkit-border-radius:4px 0 0 4px;-moz-border-radius:4px 0 0 4px;border-radius:4px 0 0 4px;display:table-cell;padding:4px 3px 3px 9px;text-align:left;vertical-align:top}div[dir=rtl] #CybotCookiebotDialogBodyLevelButtonsSelectPane{-webkit-border-radius:0 4px 4px 0;-moz-border-radius:0 4px 4px 0;border-radius:0 4px 4px 0;text-align:right}#CybotCookiebotDialogBodyLevelButtonAcceptWrapper{display:inline-block;float:right;margin-left:0;margin-right:0;pointer-events:auto}div[dir=rtl] #CybotCookiebotDialogBodyLevelButtonAcceptWrapper{display:inline-block;float:left;margin-left:0;margin-right:0}a#CybotCookiebotDialogBodyLevelButtonAccept{background-color:#006aa3;border:1px solid #006aa3;color:#ffffff;display:inline-block;font-size:9.5pt;font-weight:600;margin-left:0;margin-right:0;margin-top:6px;min-width:80px;padding:3px 10px;text-align:center;text-decoration:none;white-space:nowrap;z-index:10}a#CybotCookiebotDialogBodyLevelButtonAccept:hover{color:#ffffff;text-decoration:none}#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelectionWrapper{display:inline-block;float:right;margin-left:0;margin-right:0;padding-bottom:2px;pointer-events:auto}div[dir=rtl] #CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelectionWrapper{display:inline-block;float:left;margin-left:0;margin-right:0;padding-bottom:2px}a#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowAll,a#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelection,a#CybotCookiebotDialogBodyLevelButtonLevelOptinDeclineAll{color:#ffffff;display:inline-block;font-size:9.5pt;font-weight:600;height:16px;margin-top:6px;padding:2px 4px;text-align:center;text-decoration:none;white-space:nowrap;z-index:10}a#CybotCookiebotDialogBodyLevelButtonLevelOptinDeclineAll{background-color:#b4b0b0;border:1px solid #b4b0b0}a#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowAll{background-color:#006aa3;border:1px solid #006aa3}a#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelection{background-color:#188600;border:1px solid #188600}a#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowAll:hover,a#CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelection:hover,a#CybotCookiebotDialogBodyLevelButtonLevelOptinDeclineAll:hover{color:#ffffff;text-decoration:none}.CybotCookiebotDialogBodyLevelButtonWrapper{display:inline-block;line-height:16px;margin-left:0;margin-right:14px;position:relative}div[dir=rtl] .CybotCookiebotDialogBodyLevelButtonWrapper{margin-left:14px;margin-right:0}.CybotCookiebotDialogBodyLevelButtonWrapper:last-of-type{margin-left:0;margin-right:7px}div[dir=rtl] .CybotCookiebotDialogBodyLevelButtonWrapper:last-of-type{margin-left:7px;margin-right:0}.CybotCookiebotDialogBodyLevelButtonWrapper label{white-space:nowrap}input[type=checkbox].CybotCookiebotDialogBodyLevelButton{cursor:pointer;left:0;opacity:0;position:absolute;top:0;z-index:2}input[type=checkbox].CybotCookiebotDialogBodyLevelButton+label:after,input[type=checkbox].CybotCookiebotDialogBodyLevelButton+label:before{content:normal}input [type=checkbox].CybotCookiebotDialogBodyLevelButton.CybotCookiebotDialogBodyLevelButtonDisabled{cursor:default}input[type=checkbox].CybotCookiebotDialogBodyLevelButton+label{background-image:url();background-position:left 1px;background-repeat:no-repeat;color:inherit;cursor:pointer;display:inline-block;font-size:inherit;height:auto;left:0;line-height:16px;margin-bottom:0;margin-top:0;min-height:14px;padding:1px 0 0 17px;position:relative;top:0;vertical-align:top;width:auto;z-index:1}div[dir=rtl] input[type=checkbox].CybotCookiebotDialogBodyLevelButton+label{background-position:right 1px;padding:2px 17px 0 0}input[type=checkbox].CybotCookiebotDialogBodyLevelButton:checked+label{background-image:url();background-position:left 1px;background-repeat:no-repeat;display:inline-block;height:auto;line-height:16px;min-height:14px;padding:1px 0 0 17px;vertical-align:top;width:auto}div[dir=rtl] input[type=checkbox].CybotCookiebotDialogBodyLevelButton:checked+label{background-position:right 1px;padding:2px 17px 0 0}input[type=checkbox].CybotCookiebotDialogBodyLevelButton.CybotCookiebotDialogBodyLevelButtonDisabled+label{background-image:url();background-position:left 1px;background-repeat:no-repeat;cursor:default;display:inline-block;height:auto;left:0;line-height:16px;min-height:14px;padding:1px 0 0 17px;position:relative;top:0;vertical-align:top;width:auto;z-index:1}div[dir=rtl] input[type=checkbox].CybotCookiebotDialogBodyLevelButton.CybotCookiebotDialogBodyLevelButtonDisabled+label{background-position:right 1px;padding:2px 17px 0 0}input[type=checkbox].CybotCookiebotDialogBodyLevelButton:focus+label{background-image:url();background-position:left 1px;background-repeat:no-repeat;display:inline-block;height:auto;line-height:16px;min-height:14px;padding:1px 0 0 17px;vertical-align:top;width:auto}div[dir=rtl] input[type=checkbox].CybotCookiebotDialogBodyLevelButton:focus+label{background-position:right 1px;padding:2px 17px 0 0}input[type=checkbox].CybotCookiebotDialogBodyLevelButton:checked:focus+label{background-image:url();background-position:left 1px;background-repeat:no-repeat;display:inline-block;height:auto;line-height:16px;min-height:14px;padding:1px 0 0 17px;vertical-align:top;width:auto}div[dir=rtl] input[type=checkbox].CybotCookiebotDialogBodyLevelButton:checked:focus+label{background-position:right 1px;padding:2px 17px 0 0}#CybotCookiebotDialogBodyLevelDetailsWrapper{background-color:#ffffff;border:1px solid #ffffff;border-left:none;cursor:pointer;display:table-cell;height:14px;padding:4px 0 4px 4px;text-align:left;vertical-align:top}div[dir=rtl] #CybotCookiebotDialogBodyLevelDetailsWrapper{border:1px solid #ffffff;border-right:none;padding:4px 4px 4px 0;text-align:right}#CybotCookiebotDialogDetail{background-color:#ffffff;display:none;overflow:auto;padding-bottom:1px;padding-top:0}#CybotCookiebotDialogDetailBody{margin-left:auto;margin-right:auto;max-width:632px;vertical-align:top;width:100%}div[dir=rtl] #CybotCookiebotDialogDetailBody{text-align:right}#CybotCookiebotDialogDetailBodyContent{background-color:#ffffff;border:solid #ffffff;border-width:1px 1px 4px;color:#686666;height:170px}#CybotCookiebotDialogDetailBodyContent a{font-size:9pt}#CybotCookiebotDialogDetailBodyContentTabs a{font-size:10.5pt}#CybotCookiebotDialogDetailBodyContentText{font-size:10pt;padding:8px}#CybotCookiebotDialogDetailBodyContentTabs{display:inline-block;height:auto;position:relative;white-space:nowrap}a.CybotCookiebotDialogDetailBodyContentTabsItem{margin:0;text-decoration:none!important}a.CybotCookiebotDialogDetailBodyContentTabsItem:focus,a.CybotCookiebotDialogDetailBodyContentTabsItem:hover{background-color:#ffffff!important;border-right:1px solid #ffffff;border-top:1px solid #ffffff;color:#686666!important;opacity:.9;text-decoration:none!important}a.CybotCookiebotDialogDetailBodyContentTabsItemSelected{color:#686666!important;margin:0;opacity:1;text-decoration:none!important}a.CybotCookiebotDialogDetailBodyContentTabsItemSelected:focus,a.CybotCookiebotDialogDetailBodyContentTabsItemSelected:hover{border-right:1px solid #ffffff;border-top:1px solid #ffffff;color:#686666!important;cursor:default;text-decoration:none!important}.CybotCookiebotDialogDetailBodyContentTabsItem{background:#ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;color:#686666!important;cursor:pointer;display:inline-block;font-size:10.5pt;font-weight:400;line-height:100%;margin:1px 0 0;opacity:.85;padding:7px 18px 5px;position:relative;top:1px;white-space:normal;z-index:10}.CybotCookiebotDialogDetailBodyContentTabsItem:first-of-type{border-left:1px solid #ffffff}.CybotCookiebotDialogDetailBodyContentTabsItemSelected{background:#ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;color:#686666;display:inline-block;font-size:10.5pt;font-weight:400;line-height:100%;opacity:1;padding:8px 18px 6px;position:relative;top:1px;white-space:normal;z-index:10}.CybotCookiebotDialogDetailBodyContentTab:first-child{border-left:1px solid #ffffff;-webkit-border-radius:4px 0 0 0;-moz-border-radius:4px 0 0 0;border-radius:4px 0 0 0}div[dir=rtl] .CybotCookiebotDialogDetailBodyContentTab:first-child{border-left:none;-webkit-border-radius:0 4px 0 0;-moz-border-radius:0 4px 0 0;border-radius:0 4px 0 0}.CybotCookiebotDialogDetailBodyContentTab{border-left:none}div[dir=rtl] .CybotCookiebotDialogDetailBodyContentTab{border-left:1px solid #ffffff}#CybotCookiebotDialogDetailFooter{background-color:#ffffff;color:#686666;opacity:.85;padding-right:2px;padding-top:4px;text-align:right}div[dir=rtl] #CybotCookiebotDialogDetailFooter{text-align:left}#CybotCookiebotDialogDetailFooter a{color:#686666}#CybotCookiebotDialogDetailBodyContentTextAbout{display:none;font-size:9pt;height:140px;overflow:auto;padding:18px 12px 12px}#CybotCookiebotDialogDetailBodyContentTextOverview{display:inline-block}#CybotCookiebotDialogDetailBodyContentTextIABv2{word-wrap:break-word;display:none;text-overflow:ellipsis}#CybotCookiebotDialogDetailBodyContentTabsIABv2,#CybotCookiebotDialogDetailBodyContentTextIABv2{display:none}#CybotCookiebotDialogDetailBodyContentCookieContainerTypes,#CybotCookiebotDialogDetailBodyContentIABv2Tabs{background-color:#ffffff;float:left;font-size:9pt;padding:0;white-space:nowrap}div[dir=rtl] #CybotCookiebotDialogDetailBodyContentCookieContainerTypes,div[dir=rtl] #CybotCookiebotDialogDetailBodyContentIABv2Tabs{float:right}#CybotCookiebotDialogDetailBodyContentCookieContainerTypeDetails,#CybotCookiebotDialogDetailBodyContentIABv2Details{font-size:9pt;height:146px;max-height:146px;overflow:auto;padding:12px}.CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected,.CybotCookiebotDialogDetailBodyContentIABv2TabSelected{background-color:#ffffff;border-bottom:1px solid #ffffff;border-left:none;border-right:1px solid #ffffff;color:#686666!important;display:block;padding:8px;text-decoration:none!important}div[dir=rtl] .CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected,div[dir=rtl] .CybotCookiebotDialogDetailBodyContentIABv2TabSelected{border-left:1px solid #ffffff;border-right:none}.CybotCookiebotDialogDetailBodyContentCookieContainerTypes,.CybotCookiebotDialogDetailBodyContentIABv2Tab{background-color:#ffffff;border-bottom:1px solid #ffffff;border-left:none;border-right:1px solid #ffffff;color:#686666!important;cursor:pointer;display:block;opacity:1;padding:8px;text-decoration:none!important}.CybotCookiebotDialogDetailBodyContentCookieContainerTypes:first-child,.CybotCookiebotDialogDetailBodyContentIABv2Tab:first-child{border-top:1px solid #ffffff}.CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected:first-child{border-top:1px solid #ffffff}#CybotCookiebotDialogDetailBodyContentIABv2Tabs a:first-child{border-top:0}.CybotCookiebotDialogDetailBodyContentCookieContainerTypes label,.CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected label,.CybotCookiebotDialogDetailBodyContentIABv2Tab label,.CybotCookiebotDialogDetailBodyContentIABv2TabSelected label{cursor:pointer;display:none;margin:0}div[dir=rtl] .CybotCookiebotDialogDetailBodyContentCookieContainerTypes,div[dir=rtl] .CybotCookiebotDialogDetailBodyContentIABv2Tab{border-left:1px solid #ffffff;border-right:none}a.CybotCookiebotDialogDetailBodyContentCookieContainerTypes:focus,a.CybotCookiebotDialogDetailBodyContentCookieContainerTypes:hover,a.CybotCookiebotDialogDetailBodyContentIABv2Tab:focus,a.CybotCookiebotDialogDetailBodyContentIABv2Tab:hover{background:#ffffff!important;border-bottom:1px solid #ffffff;border-left:none;border-right:1px solid #ffffff;color:#686666!important;opacity:1;text-decoration:none!important}a.CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected:focus,a.CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected:hover,a.CybotCookiebotDialogDetailBodyContentIABv2TabSelected:focus,a.CybotCookiebotDialogDetailBodyContentIABv2TabSelected:hover{border-bottom:1px solid #ffffff;border-left:none;border-right:1px solid #ffffff;color:#686666!important;cursor:default;text-decoration:none!important}#CybotCookiebotDialogDetailBodyContentCookieTabsAdvertising,#CybotCookiebotDialogDetailBodyContentCookieTabsPreference,#CybotCookiebotDialogDetailBodyContentCookieTabsStatistics,#CybotCookiebotDialogDetailBodyContentCookieTabsUnclassified,#CybotCookiebotDialogDetailBodyContentIABv2TabFeatures,#CybotCookiebotDialogDetailBodyContentIABv2TabPartners{display:none}.CybotCookiebotDialogBodyLevelButtonIABContainer,.CybotCookiebotDialogBodyLevelButtonIABContainerCollapsed{border:1px solid #ccc;-webkit-border-radius:4px;-moz-border-radius:4px;border-radius:4px;margin-bottom:8px;overflow:hidden;padding:4px 4px 4px 8px}.CybotCookiebotDialogBodyLevelButtonIABContainerCollapsed{height:18px}.CybotCookiebotDialogBodyLevelButtonIABContainerToggleShow{background-image:url(data:image/png;base64,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);background-position:left 6px;background-position-x:left;background-position-y:6px;background-repeat:no-repeat;display:inline-block;float:right;height:20px;position:relative;width:16px}.CybotCookiebotDialogBodyLevelButtonIABContainerToggleHide{background-image:url(data:image/png;base64,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);background-position:left 6px;background-position-x:left;background-position-y:6px;background-repeat:no-repeat;display:inline-block;float:right;height:20px;position:relative;width:16px}.CybotCookiebotDialogDetailBodyContentCookieTypeTable{border-collapse:collapse;border-spacing:0;font-size:9pt;margin:8px 0 0;padding:0;width:100%}.CybotCookiebotDialogDetailBodyContentCookieTypeTable thead td,.CybotCookiebotDialogDetailBodyContentCookieTypeTable thead th{background-color:#ffffff!important;border-bottom:1px solid #ffffff;color:#686666!important;font-weight:400;padding:2px;text-align:left;vertical-align:top}div[dir=rtl] .CybotCookiebotDialogDetailBodyContentCookieTypeTable thead td,div[dir=rtl] .CybotCookiebotDialogDetailBodyContentCookieTypeTable thead th{text-align:right}.CybotCookiebotDialogDetailBodyContentCookieTypeTable tbody td{border-bottom:1px solid #ffffff;border-right:1px solid #ffffff;color:#686666!important;font-size:9pt;max-width:72px;overflow:hidden;padding:4px;text-align:left;vertical-align:top}.CybotCookiebotDialogDetailBodyContentCookieTypeTable tbody td:last-child{border-right:0}div[dir=rtl] .CybotCookiebotDialogDetailBodyContentCookieTypeTable tbody td{text-align:right}.CybotCookiebotDialogDetailBodyContentCookieTypeTable tbody td.CybotCookiebotDialogDetailBodyContentCookieTypeTableEmpty{border:none;border-top:1px solid #ffffff;padding:4px 0 0}#CybotCookiebotDialogBodyIABIntro,.CybotCookiebotDialogBodyIABIntroContainer{margin-bottom:12px}.CybotCookiebotDialogBodyLevelButtonIABHeader{font-weight:700;text-transform:uppercase}.CybotCookiebotDialogBodyLevelButtonIABHeader,.CybotCookiebotDialogBodyLevelSectionIAB{border-top:1px solid #ffffff;margin-bottom:12px;margin-top:2px;padding-top:8px}.CybotCookiebotDialogBodyLevelButtonIABDescription{margin-bottom:12px;margin-top:8px}.CybotCookiebotDialogBodyLevelButtonIABLabel{font-weight:700}ul.CybotCookiebotDialogBodyLevelButtonIABBullet{list-style-type:disc;margin:3px 0 0;padding-inline-start:18px}.CybotCookiebotDialogBodyLevelButtonIABHeaderToggle{float:right}.CybotCookiebotDialogBodyContentLabelPersonalInformation{font-weight:400!important}</style><link rel="stylesheet" type="text/css" href="/layouts/system/VisitorIdentificationCSS.aspx?tstamp=1661205176315"><style type="text/css" id="CookieConsentStateDisplayStyles">.cookieconsent-optin,.cookieconsent-optin-preferences,.cookieconsent-optin-statistics,.cookieconsent-optin-marketing{display:block;display:initial;}.cookieconsent-optout-preferences,.cookieconsent-optout-statistics,.cookieconsent-optout-marketing,.cookieconsent-optout{display:none;}</style></head>
<body class="default-device bodyclass" data-language="en"><div id="CybotCookiebotDialog" name="CybotCookiebotDialog" role="dialog" aria-describedby="CybotCookiebotDialogBodyContentTitle" lang="en" dir="ltr" ng-non-bindable="" style="display: none; opacity: 0.05; top: 951px; width: 100%; height: auto;"><div id="CybotCookiebotDialogBody"><div id="CybotCookiebotDialogPoweredbyLink" style="display: none;"><img id="CybotCookiebotDialogPoweredbyImage" src="data:," alt="logo"></div><div id="CybotCookiebotDialogBodyContent" style="padding-left: 8px;"><h2 id="CybotCookiebotDialogBodyContentTitle" lang="en">Welcome!</h2><div id="CybotCookiebotDialogBodyContentText" lang="en">We use cookies and other technologies to personalize content and ads, as well as to provide social media features on this website. By clicking “Accept” you are directing Amgen to disclose your personal information to third parties for the purposes stated above. For further information click on “Settings”             </div></div><div id="CybotCookiebotDialogBodyContentControls" style="display: none;"><div class="CybotCookiebotDialogBodyContentControlsWrapper"><input type="checkbox" id="CybotCookiebotDialogBodyContentCheckboxPersonalInformation" class="CybotCookiebotDialogBodyLevelButton" tabindex="0"> <label class="CybotCookiebotDialogBodyContentLabelPersonalInformation" for="CybotCookiebotDialogBodyContentCheckboxPersonalInformation">[#OOI_PERSONAL_INFORMATION#]</label></div></div><div id="CybotCookiebotDialogBodyButtons" style="padding-left: 0px;"><a id="CybotCookiebotDialogBodyButtonDecline" class="CybotCookiebotDialogBodyButton" href="#" tabindex="0" lang="en" style="margin-left: 2px; margin-right: 12px; width: 120px;">Decline </a><a id="CybotCookiebotDialogBodyButtonAccept" class="CybotCookiebotDialogBodyButton" href="#" tabindex="0" lang="en" style="margin-left: 2px; width: 120px;">Accept </a><a id="CybotCookiebotDialogBodyButtonDetails" class="CybotCookiebotDialogBodyLink" href="#" tabindex="0" lang="en">Settings</a></div><div id="CybotCookiebotDialogBodyLevelWrapper"><div id="CybotCookiebotDialogBodyLevelButtonAcceptWrapper"><a id="CybotCookiebotDialogBodyLevelButtonAccept" href="#" tabindex="0" lang="en">Ok</a></div><div id="CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelectionWrapper" style="display:none"><a id="CybotCookiebotDialogBodyLevelButtonLevelOptinDeclineAll" class="CybotCookiebotDialogBodyButton" href="#" tabindex="0" lang="en">Decline </a><a id="CybotCookiebotDialogBodyLevelButtonLevelOptinAllowallSelection" class="CybotCookiebotDialogBodyButton" href="#" tabindex="0" lang="en"> </a><a id="CybotCookiebotDialogBodyLevelButtonLevelOptinAllowAll" class="CybotCookiebotDialogBodyButton" href="#" tabindex="0" lang="en">Decline</a></div><div id="CybotCookiebotDialogBodyLevelButtons"><div id="CybotCookiebotDialogBodyLevelButtonsTable"><div id="CybotCookiebotDialogBodyLevelButtonsRow"><div id="CybotCookiebotDialogBodyLevelButtonsSelectPane"><div class="CybotCookiebotDialogBodyLevelButtonWrapper"><input type="checkbox" id="CybotCookiebotDialogBodyLevelButtonNecessary" class="CybotCookiebotDialogBodyLevelButton CybotCookiebotDialogBodyLevelButtonDisabled" disabled="disabled" checked="checked"> <label for="CybotCookiebotDialogBodyLevelButtonNecessary">Strictly Necessary Cookies</label></div><div class="CybotCookiebotDialogBodyLevelButtonWrapper"><input type="checkbox" id="CybotCookiebotDialogBodyLevelButtonPreferences" class="CybotCookiebotDialogBodyLevelButton" checked="checked" tabindex="0"> <label for="CybotCookiebotDialogBodyLevelButtonPreferences">Functional Cookies</label></div><div class="CybotCookiebotDialogBodyLevelButtonWrapper"><input type="checkbox" id="CybotCookiebotDialogBodyLevelButtonStatistics" class="CybotCookiebotDialogBodyLevelButton" checked="checked" tabindex="0"> <label for="CybotCookiebotDialogBodyLevelButtonStatistics">Performance</label></div><div class="CybotCookiebotDialogBodyLevelButtonWrapper"><input type="checkbox" id="CybotCookiebotDialogBodyLevelButtonMarketing" class="CybotCookiebotDialogBodyLevelButton" checked="checked" tabindex="0"> <label for="CybotCookiebotDialogBodyLevelButtonMarketing">Social Media Cookies</label></div></div><div id="CybotCookiebotDialogBodyLevelDetailsWrapper"><a id="CybotCookiebotDialogBodyLevelDetailsButton" class="CybotCookiebotDialogBodyLink" href="#" tabindex="0" lang="en">Settings</a></div></div></div></div></div></div><div id="CybotCookiebotDialogDetail"><div id="CybotCookiebotDialogDetailBody"><div id="CybotCookiebotDialogDetailBodyContentTabs"><a id="CybotCookiebotDialogDetailBodyContentTabsOverview" class="CybotCookiebotDialogDetailBodyContentTab CybotCookiebotDialogDetailBodyContentTabsItemSelected" href="#" lang="en">Cookie declaration </a><a id="CybotCookiebotDialogDetailBodyContentTabsIABv2" class="CybotCookiebotDialogDetailBodyContentTab CybotCookiebotDialogDetailBodyContentTabsItem" href="#" lang="en" style="display: none;">[#IABV2SETTINGS#] </a><a id="CybotCookiebotDialogDetailBodyContentTabsAbout" class="CybotCookiebotDialogDetailBodyContentTab CybotCookiebotDialogDetailBodyContentTabsItem" href="#" lang="en">About</a></div><div id="CybotCookiebotDialogDetailBodyContent"><div id="CybotCookiebotDialogDetailBodyContentTextOverview" lang="en"><div id="CybotCookiebotDialogDetailBodyContentCookieContainer"><div id="CybotCookiebotDialogDetailBodyContentCookieContainerTypes"><a id="CybotCookiebotDialogDetailBodyContentCookieContainerNecessary" href="#" class="CybotCookiebotDialogDetailBodyContentCookieContainerTypesSelected" lang="en" aria-label="Strictly Necessary Cookies (6)"><label for="CybotCookiebotDialogDetailBodyContentCookieContainerNecessary" aria-hidden="true"> </label>Strictly Necessary Cookies (6)</a> <a id="CybotCookiebotDialogDetailBodyContentCookieContainerPreference" href="#" class="CybotCookiebotDialogDetailBodyContentCookieContainerTypes" lang="en" aria-label="Functional Cookies (1)"><label for="CybotCookiebotDialogDetailBodyContentCookieContainerPreference" aria-hidden="true"> </label>Functional Cookies (1)</a> <a id="CybotCookiebotDialogDetailBodyContentCookieContainerStatistics" href="#" class="CybotCookiebotDialogDetailBodyContentCookieContainerTypes" lang="en" aria-label="Performance (5)"><label for="CybotCookiebotDialogDetailBodyContentCookieContainerStatistics" aria-hidden="true"> </label>Performance (5)</a> <a id="CybotCookiebotDialogDetailBodyContentCookieContainerAdvertising" href="#" class="CybotCookiebotDialogDetailBodyContentCookieContainerTypes" lang="en" aria-label="Social Media Cookies (1)"><label for="CybotCookiebotDialogDetailBodyContentCookieContainerAdvertising" aria-hidden="true"> </label>Social Media Cookies (1)</a> <a id="CybotCookiebotDialogDetailBodyContentCookieContainerUnclassified" href="#" class="CybotCookiebotDialogDetailBodyContentCookieContainerTypes" lang="en" aria-label="Unknown (2)"><label for="CybotCookiebotDialogDetailBodyContentCookieContainerUnclassified" aria-hidden="true"> </label>Unknown (2)</a></div><div id="CybotCookiebotDialogDetailBodyContentCookieContainerTypeDetails"><div id="CybotCookiebotDialogDetailBodyContentCookieTabsNecessary"><div class="CybotCookiebotDialogDetailBodyContentCookieTypeIntro">These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. &nbsp; &nbsp;You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information</div><div class="CybotCookiebotDialogDetailBodyContentCookieTypeTableContainer"><table id="CybotCookiebotDialogDetailTableNecessary" class="CybotCookiebotDialogDetailBodyContentCookieTypeTable"><thead><tr><th scope="col">Name</th><th scope="col">Provider</th><th scope="col">Purpose</th><th scope="col">Expiry</th><th scope="col">Type</th></tr></thead><tbody><tr><td title="__RequestVerificationToken">__RequestVerificationToken</td><td>www.amgenpipeline.com</td><td title="Helps prevent Cross-Site Request Forgery (CSRF) attacks.">Helps prevent Cross-Site Request Forgery (CSRF) attacks.</td><td title="Session">Session</td><td title="HTTP">HTTP</td></tr><tr><td title="ASP.NET_SessionId">ASP.NET_SessionId</td><td>www.amgenpipeline.com</td><td title="Preserves the visitor's session state across page requests.">Preserves the visitor's session state across page requests.</td><td title="Session">Session</td><td title="HTTP">HTTP</td></tr><tr><td title="AWSALB">AWSALB</td><td>www.amgenpipeline.com</td><td title="Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.  ">Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.  </td><td title="6 days">6 days</td><td title="HTTP">HTTP</td></tr><tr><td title="AWSALBCORS">AWSALBCORS</td><td>www.amgenpipeline.com</td><td title="Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.  ">Registers which server-cluster is serving the visitor. This is used in context with load balancing, in order to optimize user experience.  </td><td title="6 days">6 days</td><td title="HTTP">HTTP</td></tr><tr><td title="CookieConsent">CookieConsent</td><td><a href="https://www.cookiebot.com/goto/privacy-policy/" target="_blank" rel="noopener noreferrer nofollow" title="Cookiebot's privacy policy">Cookiebot</a></td><td title="Stores the user's cookie consent state for the current domain">Stores the user's cookie consent state for the current domain</td><td title="1 year">1 year</td><td title="HTTP">HTTP</td></tr><tr><td title="sxa_site">sxa_site</td><td>www.amgenpipeline.com</td><td title="Improves website speed and implements content through a Content Delivery Network (CDN). ">Improves website speed and implements content through a Content Delivery Network (CDN). </td><td title="Session">Session</td><td title="HTTP">HTTP</td></tr></tbody></table></div></div><div id="CybotCookiebotDialogDetailBodyContentCookieTabsPreference"><div class="CybotCookiebotDialogDetailBodyContentCookieTypeIntro">These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. &nbsp; &nbsp;If you do not allow these cookies then some or all of these services may not function properly.</div><div class="CybotCookiebotDialogDetailBodyContentCookieTypeTableContainer"><table id="CybotCookiebotDialogDetailTablePreference" class="CybotCookiebotDialogDetailBodyContentCookieTypeTable"><thead><tr><th scope="col">Name</th><th scope="col">Provider</th><th scope="col">Purpose</th><th scope="col">Expiry</th><th scope="col">Type</th></tr></thead><tbody><tr><td title="shell#lang">shell#lang</td><td>www.amgenpipeline.com</td><td title="This cookie is used to determine the preferred language of the visitor and sets the language accordingly on the website, if possible.">This cookie is used to determine the preferred language of the visitor and sets the language accordingly on the website, if possible.</td><td title="Session">Session</td><td title="HTTP">HTTP</td></tr></tbody></table></div></div><div id="CybotCookiebotDialogDetailBodyContentCookieTabsStatistics"><div class="CybotCookiebotDialogDetailBodyContentCookieTypeIntro">These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. &nbsp; &nbsp;All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.</div><div class="CybotCookiebotDialogDetailBodyContentCookieTypeTableContainer"><table id="CybotCookiebotDialogDetailTableStatistics" class="CybotCookiebotDialogDetailBodyContentCookieTypeTable"><thead><tr><th scope="col">Name</th><th scope="col">Provider</th><th scope="col">Purpose</th><th scope="col">Expiry</th><th scope="col">Type</th></tr></thead><tbody><tr><td title="_ga">_ga</td><td><a href="https://policies.google.com/privacy" target="_blank" rel="noopener noreferrer nofollow" title="Google's privacy policy">Google</a></td><td title="Registers a unique ID that is used to generate statistical data on how the visitor uses the website.">Registers a unique ID that is used to generate statistical data on how the visitor uses the website.</td><td title="2 years">2 years</td><td title="HTTP">HTTP</td></tr><tr><td title="_ga_#">_ga_#</td><td><a href="https://policies.google.com/privacy" target="_blank" rel="noopener noreferrer nofollow" title="Google's privacy policy">Google</a></td><td title="Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. ">Used by Google Analytics to collect data on the number of times a user has visited the website as well as dates for the first and most recent visit. </td><td title="2 years">2 years</td><td title="HTTP">HTTP</td></tr><tr><td title="_gat">_gat</td><td><a href="https://policies.google.com/privacy" target="_blank" rel="noopener noreferrer nofollow" title="Google's privacy policy">Google</a></td><td title="Used by Google Analytics to throttle request rate">Used by Google Analytics to throttle request rate</td><td title="1 day">1 day</td><td title="HTTP">HTTP</td></tr><tr><td title="_gid">_gid</td><td><a href="https://policies.google.com/privacy" target="_blank" rel="noopener noreferrer nofollow" title="Google's privacy policy">Google</a></td><td title="Registers a unique ID that is used to generate statistical data on how the visitor uses the website.">Registers a unique ID that is used to generate statistical data on how the visitor uses the website.</td><td title="1 day">1 day</td><td title="HTTP">HTTP</td></tr><tr><td title="SC_ANALYTICS_GLOBAL_COOKIE">SC_ANALYTICS_GLOBAL_COOKIE</td><td>www.amgenpipeline.com</td><td title="Used by Sitecore Engagement Analytics to identify the visitor on repeat visits to the website.">Used by Sitecore Engagement Analytics to identify the visitor on repeat visits to the website.</td><td title="10 years">10 years</td><td title="HTTP">HTTP</td></tr></tbody></table></div></div><div id="CybotCookiebotDialogDetailBodyContentCookieTabsAdvertising"><div class="CybotCookiebotDialogDetailBodyContentCookieTypeIntro">These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. &nbsp; &nbsp;If you do not allow these cookies you may not be able to use or see these sharing tools.</div><div class="CybotCookiebotDialogDetailBodyContentCookieTypeTableContainer"><table id="CybotCookiebotDialogDetailTableAdvertising" class="CybotCookiebotDialogDetailBodyContentCookieTypeTable"><thead><tr><th scope="col">Name</th><th scope="col">Provider</th><th scope="col">Purpose</th><th scope="col">Expiry</th><th scope="col">Type</th></tr></thead><tbody><tr><td title="ads/ga-audiences">ads/ga-audiences</td><td><a href="https://policies.google.com/privacy" target="_blank" rel="noopener noreferrer nofollow" title="Google's privacy policy">Google</a></td><td title="Used by Google AdWords to re-engage visitors that are likely to convert to customers based on the visitor's online behaviour across websites.">Used by Google AdWords to re-engage visitors that are likely to convert to customers based on the visitor's online behaviour across websites.</td><td title="Session">Session</td><td title="Pixel">Pixel</td></tr></tbody></table></div></div><div id="CybotCookiebotDialogDetailBodyContentCookieTabsUnclassified"><div class="CybotCookiebotDialogDetailBodyContentCookieTypeIntro">Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.</div><div class="CybotCookiebotDialogDetailBodyContentCookieTypeTableContainer"><table id="CybotCookiebotDialogDetailTableUnclassified" class="CybotCookiebotDialogDetailBodyContentCookieTypeTable"><thead><tr><th scope="col">Name</th><th scope="col">Provider</th><th scope="col">Purpose</th><th scope="col">Expiry</th><th scope="col">Type</th></tr></thead><tbody><tr><td title="IgnoreTrackerSpotting">IgnoreTrackerSpotting</td><td>www.amgenpipeline.com</td><td title="Pending">Pending</td><td title="1 day">1 day</td><td title="HTTP">HTTP</td></tr><tr><td title="pipelineData">pipelineData</td><td>www.amgenpipeline.com</td><td title="Pending">Pending</td><td title="Session">Session</td><td title="HTML">HTML</td></tr></tbody></table></div></div></div></div></div><div id="CybotCookiebotDialogDetailBodyContentTextIABv2" lang="en"><div id="CybotCookiebotDialogDetailBodyContentIABContainer"><div id="CybotCookiebotDialogDetailBodyContentIABv2Tabs"><a id="CybotCookiebotDialogDetailBodyContentIABv2Purposes" href="#" class="CybotCookiebotDialogDetailBodyContentIABv2TabSelected" lang="en" aria-label="[#IABV2_LABEL_PURPOSES#]"><label for="CybotCookiebotDialogDetailBodyContentIABv2Purposes" aria-hidden="true"> </label>[#IABV2_LABEL_PURPOSES#]</a> <a id="CybotCookiebotDialogDetailBodyContentIABv2Features" href="#" class="CybotCookiebotDialogDetailBodyContentIABv2Tab" lang="en" aria-label="[#IABV2_LABEL_FEATURES#]"><label for="CybotCookiebotDialogDetailBodyContentIABv2Features" aria-hidden="true"> </label>[#IABV2_LABEL_FEATURES#]</a> <a id="CybotCookiebotDialogDetailBodyContentIABv2Partners" href="#" class="CybotCookiebotDialogDetailBodyContentIABv2Tab" lang="en" aria-label="[#IABV2_LABEL_PARTNERS#]"><label for="CybotCookiebotDialogDetailBodyContentIABv2Partners" aria-hidden="true"> </label>[#IABV2_LABEL_PARTNERS#]</a></div><div id="CybotCookiebotDialogDetailBodyContentIABv2Details"><div id="CybotCookiebotDialogDetailBodyContentIABv2TabPurposes"><div class="CybotCookiebotDialogDetailBodyContentIABv2PurposesBody">[#IABV2_BODY_PURPOSES#]</div></div><div id="CybotCookiebotDialogDetailBodyContentIABv2TabFeatures"><div class="CybotCookiebotDialogDetailBodyContentIABv2FeaturesBody">[#IABV2_BODY_FEATURES#]</div></div><div id="CybotCookiebotDialogDetailBodyContentIABv2TabPartners"><div class="CybotCookiebotDialogDetailBodyContentIABv2PartnersBody">[#IABV2_BODY_PARTNERS#]</div></div></div></div></div><div id="CybotCookiebotDialogDetailBodyContentTextAbout" lang="en"><p style="">Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies&nbsp; we need your permission. </p><p style="">This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.</p><p style="">For further information please visit <a href="http://www.amgen.eu/cookie-information-for-users/" style="" target="_blank">www.amgen.eu/cookie-information-for-users/</a></p></div></div><div id="CybotCookiebotDialogDetailFooter" lang="en">Cookie declaration last updated on 8/10/22 by <a href="https://www.cookiebot.com" target="_blank" rel="noopener" title="Cookiebot">Cookiebot</a></div></div></div></div>
    
    


    <!-- Google Tag Manager (noscript) -->
    <noscript>
        <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-M4CP89H"
                height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <!-- End Google Tag Manager (noscript) -->


    <div id="fb-root"></div>
    <div id="wrapper">
    </div>
    
    <header class="header-nav">
        



<div class="component container col-12" id="pipeline-header">
    <div class="component-content">



<div class="component row-splitter">
        <div class="container-fluid">
            <div>
                

<div class="row component column-splitter">
        <div class="col-6">
                    <a class="quantum-header__logo gtm-header" href="/">
            <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/amgen-logo.svg?h=36&amp;w=151&amp;la=en&amp;hash=047A41224BAD77E1DD4DA6252B9E441C" class="quantum-header__logo" alt="logo">
        </a>


        </div>
        <div class="col-6 position-right">
            
        <button class="quantum-button quantum-hero__button" type="button"><span class="quantum-button__text"><a href="/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/pdf/amgen-pipeline-chart.pdf" class="quantum-button__text " target="_blank" data-click-type="download" data-click-text="Download Pipeline Chart">Download pipeline chart</a></span></button></div>
</div>
            </div>
        </div>
</div>    </div>
</div>
    </header>

    <div class="hero-div">
        

    <div class="quantum-hero quantum-hero--image-position-default quantum-container--primary quantum-hero--multiple-background-images">
        <div class="quantum-hero__inner lozad-background lozad" style="background-image:url(-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Desktop/Pipeline/HeroImage3.jpg),url(-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Mobile/Pipeline/heroimage.jpg)">

        </div>
        <div class="quantum-hero__text">
            <div class="quantum-hero__text-inner quantum-long-form-text">

                <h5>A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.</h5>

                <h2> PIPELINE</h2>



                    <button class="quantum-button quantum-hero__button" type="button">
                        <span class="quantum-button__text">
                            <a href="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/PDF/amgen-pipeline-chart.pdf" class="quantum-button__text " data-click-type="download" data-click-text="Download Pipeline Chart" target="_blank">
                                Download Pipeline Chart
                            </a>
                        </span>
                    </button>


            </div>

        </div>
    </div>

    </div>
    <div class="banner-div">
        
    </div>
    
    

<div class="filter-section" id="filter-section">
    <input name="__RequestVerificationToken" type="hidden" value="7mGva9PQ-EljEjrcJzOKEH47FC_IiVs7OOPBQG7m82PkBhUxwXDSYetkxigsU64GUO8W9S9-aG07_A3qsqQeJzL0Mz3IKGsmRv90aey_03c1">
    <div class="filter-block">
        <div class="container filter-container">
            <div class="row searchActive">
                <div class="filter-btn-container">
                    <a class="filter-btn">
                        
                        <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/icon-filter.png?h=22&amp;w=22&amp;la=en&amp;hash=33D06DD4E4E88554AD019A442B62EB1D" class="icon-filter lozad" alt="icon-filter">
                        
                        <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/icon-filter-close.png?h=33&amp;w=33&amp;la=en&amp;hash=DA93893BE2B19F6B54D19F53EEC523EF" class="icon-filter-close lozad" alt="close">
                        <span class="filter-text">FILTER</span>
                    </a>
                </div>
                <div class="search-btn-container ">
                    <div class="input-group d-none d-md-block">
                        <input type="search" class="form-control search-input" placeholder="Search our pipeline">
                        <a class="search-btn" data-click-type="promo" data-click-text="search">
                            
                            <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/icon-search.png?h=20&amp;w=20&amp;la=en&amp;hash=63874C92E8AA4A2E841FD1C9890FF630" class="icon-search lozad" alt="icon-filter">
                        </a>
                    </div>
                    <div class="mobileSearch d-block d-md-none">
                        <button type="button" class="btn mblButtonSearch">
                            SEARCH
                            
                            <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/icon-search.png?h=20&amp;w=20&amp;la=en&amp;hash=63874C92E8AA4A2E841FD1C9890FF630" class="icon-search lozad" alt="icon-filter">

                        </button>
                    </div>
                </div>
            </div>
            <div class="mblSearchContent">
                <div class="row clearfix">
                    <div class=" mbl-input-group">
                        <div class="input-group ">
                            <input type="search" class="form-control search-input" placeholder="Search our pipeline">
                            <a class="search-btn" data-click-type="promo" data-click-text="search">
                                
                                <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/icon-search.png?h=20&amp;w=20&amp;la=en&amp;hash=63874C92E8AA4A2E841FD1C9890FF630" class="icon-search lozad" alt="icon-filter">
                            </a>
                        </div>
                    </div>
                    <a class="closeSearch">
                        
                        <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/icon-filter-close.png?h=33&amp;w=33&amp;la=en&amp;hash=DA93893BE2B19F6B54D19F53EEC523EF" class="close lozad" alt="close">
                    </a>
                </div>
            </div>
        </div>
    </div>
    <div class="filter-element-block">
        <div class="container filter-element-container">
            <div class="row">
                <div class="col-md-3">
                    <div class="filter-box-area" id="therapeuticAreaContainer"><p class="filter-box-title">THERAPEUTIC AREA</p><p><input type="checkbox" checked="" id="TAall" name="TAall"><label for="TAall"> All Areas</label></p><p><input type="checkbox" id="TA1" name="TA1"><label for="TA1"> Bone</label></p><p><input type="checkbox" id="TA2" name="TA2"><label for="TA2"> Cardiometabolic</label></p><p><input type="checkbox" id="TA3" name="TA3"><label for="TA3"> Hematology / Oncology</label></p><p><input type="checkbox" id="TA4" name="TA4"><label for="TA4"> Inflammation</label></p><p><input type="checkbox" id="TA5" name="TA5"><label for="TA5"> Metabolic Disorders</label></p><p><input type="checkbox" id="TA6" name="TA6"><label for="TA6"> Nephrology</label></p><p><input type="checkbox" id="TA7" name="TA7"><label for="TA7"> Neuroscience</label></p></div>
                </div>
                <div class="col-md-3 ">
                    <div class="filter-box-area">
                        <p class="filter-box-title">
                            Investigational Indication
                        </p>
                        <div class="dropdown">
                            <div id="indicationContainerId" class="indicationContainer"><div id="comboTree591561Wrapper" class="comboTreeWrapper"><div id="comboTree591561InputWrapper" class="comboTreeInputWrapper"><input type="text" id="indicationDropdown" placeholder="Please select" readonly="" class="comboTreeInputBox"><button id="comboTree591561ArrowBtn" class="comboTreeArrowBtn" type="button"><span class="comboTreeArrowBtnImg"><img src="/-/media/themes/amgen/amgenpipeline-com/amgenpipeline-com/images/common/indication-arrow.png" class="down-arrow"></span></button></div><div id="comboTree591561DropDownContainer" class="comboTreeDropDownContainer"><input id="comboTree591561MultiFilter" type="text" class="multiplesFilter" placeholder="Search here..."><ul><li class="ComboTreeItemChlid"> <span data-id="IN1" class="comboTreeItemTitle"><input type="checkbox" id="IN1" name="IN1"><label class="indication-checkbox-title" name="indicationLabel" for="IN1"> Acute Lymphoblastic Leukemia</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN2" class="comboTreeItemTitle"><input type="checkbox" id="IN2" name="IN2"><label class="indication-checkbox-title" name="indicationLabel" for="IN2"> Acute Myeloid Leukemia</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN3" class="comboTreeItemTitle"><input type="checkbox" id="IN3" name="IN3"><label class="indication-checkbox-title" name="indicationLabel" for="IN3"> Acute Radiation Syndrome (ARS)</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN4" class="comboTreeItemTitle"><input type="checkbox" id="IN4" name="IN4"><label class="indication-checkbox-title" name="indicationLabel" for="IN4"> Advanced Colorectal Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN5" class="comboTreeItemTitle"><input type="checkbox" id="IN5" name="IN5"><label class="indication-checkbox-title" name="indicationLabel" for="IN5"> Asthma</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN6" class="comboTreeItemTitle"><input type="checkbox" id="IN6" name="IN6"><label class="indication-checkbox-title" name="indicationLabel" for="IN6"> Atopic Dermatitis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN7" class="comboTreeItemTitle"><input type="checkbox" id="IN7" name="IN7"><label class="indication-checkbox-title" name="indicationLabel" for="IN7"> Behcet's Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN8" class="comboTreeItemTitle"><input type="checkbox" id="IN8" name="IN8"><label class="indication-checkbox-title" name="indicationLabel" for="IN8"> Biosimilar candidate to EYLEA</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN9" class="comboTreeItemTitle"><input type="checkbox" id="IN9" name="IN9"><label class="indication-checkbox-title" name="indicationLabel" for="IN9"> Biosimilar candidate to Soliris</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN10" class="comboTreeItemTitle"><input type="checkbox" id="IN10" name="IN10"><label class="indication-checkbox-title" name="indicationLabel" for="IN10"> Biosimilar candidate to STELARA</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN11" class="comboTreeItemTitle"><input type="checkbox" id="IN11" name="IN11"><label class="indication-checkbox-title" name="indicationLabel" for="IN11"> Breast Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN12" class="comboTreeItemTitle"><input type="checkbox" id="IN12" name="IN12"><label class="indication-checkbox-title" name="indicationLabel" for="IN12"> Cardiovascular Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN13" class="comboTreeItemTitle"><input type="checkbox" id="IN13" name="IN13"><label class="indication-checkbox-title" name="indicationLabel" for="IN13"> Celiac Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN14" class="comboTreeItemTitle"><input type="checkbox" id="IN14" name="IN14"><label class="indication-checkbox-title" name="indicationLabel" for="IN14"> Chemotherapy-Induced Thrombocytopenia</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN15" class="comboTreeItemTitle"><input type="checkbox" id="IN15" name="IN15"><label class="indication-checkbox-title" name="indicationLabel" for="IN15"> Chronic Kidney Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN16" class="comboTreeItemTitle"><input type="checkbox" id="IN16" name="IN16"><label class="indication-checkbox-title" name="indicationLabel" for="IN16"> Chronic Obstructive Pulmonary Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN17" class="comboTreeItemTitle"><input type="checkbox" id="IN17" name="IN17"><label class="indication-checkbox-title" name="indicationLabel" for="IN17"> Chronic Rhinosinusitis with Nasal Polyps</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN18" class="comboTreeItemTitle"><input type="checkbox" id="IN18" name="IN18"><label class="indication-checkbox-title" name="indicationLabel" for="IN18"> Chronic Spontaneous Urticaria</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN19" class="comboTreeItemTitle"><input type="checkbox" id="IN19" name="IN19"><label class="indication-checkbox-title" name="indicationLabel" for="IN19"> Colorectal Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN20" class="comboTreeItemTitle"><input type="checkbox" id="IN20" name="IN20"><label class="indication-checkbox-title" name="indicationLabel" for="IN20"> COVID-19</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN21" class="comboTreeItemTitle"><input type="checkbox" id="IN21" name="IN21"><label class="indication-checkbox-title" name="indicationLabel" for="IN21"> Early Immune&nbsp;Thrombocytopenia Purpura</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN22" class="comboTreeItemTitle"><input type="checkbox" id="IN22" name="IN22"><label class="indication-checkbox-title" name="indicationLabel" for="IN22"> EYLEA® biosimilarity</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN23" class="comboTreeItemTitle"><input type="checkbox" id="IN23" name="IN23"><label class="indication-checkbox-title" name="indicationLabel" for="IN23"> Gastric Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN24" class="comboTreeItemTitle"><input type="checkbox" id="IN24" name="IN24"><label class="indication-checkbox-title" name="indicationLabel" for="IN24"> Gastric and Gastroesophageal Junction (GEJ) Cancers</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN25" class="comboTreeItemTitle"><input type="checkbox" id="IN25" name="IN25"><label class="indication-checkbox-title" name="indicationLabel" for="IN25"> Gastroesophageal Junction Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN26" class="comboTreeItemTitle"><input type="checkbox" id="IN26" name="IN26"><label class="indication-checkbox-title" name="indicationLabel" for="IN26"> Genital Psoriasis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN27" class="comboTreeItemTitle"><input type="checkbox" id="IN27" name="IN27"><label class="indication-checkbox-title" name="indicationLabel" for="IN27"> Glioblastoma</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN28" class="comboTreeItemTitle"><input type="checkbox" id="IN28" name="IN28"><label class="indication-checkbox-title" name="indicationLabel" for="IN28"> Graft Versus Host Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN29" class="comboTreeItemTitle"><input type="checkbox" id="IN29" name="IN29"><label class="indication-checkbox-title" name="indicationLabel" for="IN29"> Heart Failure</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN30" class="comboTreeItemTitle"><input type="checkbox" id="IN30" name="IN30"><label class="indication-checkbox-title" name="indicationLabel" for="IN30"> Hematology</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN31" class="comboTreeItemTitle"><input type="checkbox" id="IN31" name="IN31"><label class="indication-checkbox-title" name="indicationLabel" for="IN31"> Hypercholesterolemia</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN32" class="comboTreeItemTitle"><input type="checkbox" id="IN32" name="IN32"><label class="indication-checkbox-title" name="indicationLabel" for="IN32"> Inflammatory Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN33" class="comboTreeItemTitle"><input type="checkbox" id="IN33" name="IN33"><label class="indication-checkbox-title" name="indicationLabel" for="IN33"> Interchangeability</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN34" class="comboTreeItemTitle"><input type="checkbox" id="IN34" name="IN34"><label class="indication-checkbox-title" name="indicationLabel" for="IN34"> Investigational Biosimilar</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN35" class="comboTreeItemTitle"><input type="checkbox" id="IN35" name="IN35"><label class="indication-checkbox-title" name="indicationLabel" for="IN35"> Juvenile Psoriatic Arthritis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN36" class="comboTreeItemTitle"><input type="checkbox" id="IN36" name="IN36"><label class="indication-checkbox-title" name="indicationLabel" for="IN36"> Male Osteoporosis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN37" class="comboTreeItemTitle"><input type="checkbox" id="IN37" name="IN37"><label class="indication-checkbox-title" name="indicationLabel" for="IN37"> Metastatic Gastric and Gastroesophageal Junction Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN38" class="comboTreeItemTitle"><input type="checkbox" id="IN38" name="IN38"><label class="indication-checkbox-title" name="indicationLabel" for="IN38"> Metastatic Melanoma</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN39" class="comboTreeItemTitle"><input type="checkbox" id="IN39" name="IN39"><label class="indication-checkbox-title" name="indicationLabel" for="IN39"> Migraine</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN40" class="comboTreeItemTitle"><input type="checkbox" id="IN40" name="IN40"><label class="indication-checkbox-title" name="indicationLabel" for="IN40"> Mild to Moderate Plaque Psoriasis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN41" class="comboTreeItemTitle"><input type="checkbox" id="IN41" name="IN41"><label class="indication-checkbox-title" name="indicationLabel" for="IN41"> Multiple Myeloma</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN42" class="comboTreeItemTitle"><input type="checkbox" id="IN42" name="IN42"><label class="indication-checkbox-title" name="indicationLabel" for="IN42"> Neuroendocrine Prostate Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN43" class="comboTreeItemTitle"><input type="checkbox" id="IN43" name="IN43"><label class="indication-checkbox-title" name="indicationLabel" for="IN43"> Nonalcoholic Steatohepatitis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN44" class="comboTreeItemTitle"><input type="checkbox" id="IN44" name="IN44"><label class="indication-checkbox-title" name="indicationLabel" for="IN44"> Non-Hodgkin's Lymphoma</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN45" class="comboTreeItemTitle"><input type="checkbox" id="IN45" name="IN45"><label class="indication-checkbox-title" name="indicationLabel" for="IN45"> Non-Small Cell Lung Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN46" class="comboTreeItemTitle"><input type="checkbox" id="IN46" name="IN46"><label class="indication-checkbox-title" name="indicationLabel" for="IN46"> Obesity</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN47" class="comboTreeItemTitle"><input type="checkbox" id="IN47" name="IN47"><label class="indication-checkbox-title" name="indicationLabel" for="IN47"> Osteoporosis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN48" class="comboTreeItemTitle"><input type="checkbox" id="IN48" name="IN48"><label class="indication-checkbox-title" name="indicationLabel" for="IN48"> Other Tumors</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN49" class="comboTreeItemTitle"><input type="checkbox" id="IN49" name="IN49"><label class="indication-checkbox-title" name="indicationLabel" for="IN49"> Palmoplantar Pustulosis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN50" class="comboTreeItemTitle"><input type="checkbox" id="IN50" name="IN50"><label class="indication-checkbox-title" name="indicationLabel" for="IN50"> Pediatric Acute Lymphoblastic Leukemia</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN51" class="comboTreeItemTitle"><input type="checkbox" id="IN51" name="IN51"><label class="indication-checkbox-title" name="indicationLabel" for="IN51"> Pediatric Behcet’s Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN52" class="comboTreeItemTitle"><input type="checkbox" id="IN52" name="IN52"><label class="indication-checkbox-title" name="indicationLabel" for="IN52"> Pediatric Familial Hypercholesterolemia</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN53" class="comboTreeItemTitle"><input type="checkbox" id="IN53" name="IN53"><label class="indication-checkbox-title" name="indicationLabel" for="IN53"> Pediatric Glucocorticoid-Induced Osteoporosis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN54" class="comboTreeItemTitle"><input type="checkbox" id="IN54" name="IN54"><label class="indication-checkbox-title" name="indicationLabel" for="IN54"> Pediatric Migraine</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN55" class="comboTreeItemTitle"><input type="checkbox" id="IN55" name="IN55"><label class="indication-checkbox-title" name="indicationLabel" for="IN55"> Pediatric Osteogenesis Imperfecta</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN56" class="comboTreeItemTitle"><input type="checkbox" id="IN56" name="IN56"><label class="indication-checkbox-title" name="indicationLabel" for="IN56"> Pediatric Secondary Hyperparathyroidism</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN57" class="comboTreeItemTitle"><input type="checkbox" id="IN57" name="IN57"><label class="indication-checkbox-title" name="indicationLabel" for="IN57"> Pediatric Heart Failure</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN58" class="comboTreeItemTitle"><input type="checkbox" id="IN58" name="IN58"><label class="indication-checkbox-title" name="indicationLabel" for="IN58"> Pediatric Plaque Psoriasis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN59" class="comboTreeItemTitle"><input type="checkbox" id="IN59" name="IN59"><label class="indication-checkbox-title" name="indicationLabel" for="IN59"> Prostate Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN60" class="comboTreeItemTitle"><input type="checkbox" id="IN60" name="IN60"><label class="indication-checkbox-title" name="indicationLabel" for="IN60"> Psoriasis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN61" class="comboTreeItemTitle"><input type="checkbox" id="IN61" name="IN61"><label class="indication-checkbox-title" name="indicationLabel" for="IN61"> Respiratory Disease</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN62" class="comboTreeItemTitle"><input type="checkbox" id="IN62" name="IN62"><label class="indication-checkbox-title" name="indicationLabel" for="IN62"> Rheumatoid Arthritis</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN63" class="comboTreeItemTitle"><input type="checkbox" id="IN63" name="IN63"><label class="indication-checkbox-title" name="indicationLabel" for="IN63"> Rituxan® /MabThera™ biosimilarity</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN64" class="comboTreeItemTitle"><input type="checkbox" id="IN64" name="IN64"><label class="indication-checkbox-title" name="indicationLabel" for="IN64"> Severe Asthma</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN65" class="comboTreeItemTitle"><input type="checkbox" id="IN65" name="IN65"><label class="indication-checkbox-title" name="indicationLabel" for="IN65"> Small-Cell Lung Cancer</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN66" class="comboTreeItemTitle"><input type="checkbox" id="IN66" name="IN66"><label class="indication-checkbox-title" name="indicationLabel" for="IN66"> Solid Tumors</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN67" class="comboTreeItemTitle"><input type="checkbox" id="IN67" name="IN67"><label class="indication-checkbox-title" name="indicationLabel" for="IN67"> STELARA® biosimilarity</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN68" class="comboTreeItemTitle"><input type="checkbox" id="IN68" name="IN68"><label class="indication-checkbox-title" name="indicationLabel" for="IN68"> Systemic Lupus Erythematosus</label></span></li><li class="ComboTreeItemChlid"> <span data-id="IN69" class="comboTreeItemTitle"><input type="checkbox" id="IN69" name="IN69"><label class="indication-checkbox-title" name="indicationLabel" for="IN69"> Ulcerative Colitis</label></span></li></ul></div></div></div>
                        </div>
                    </div>
                </div>
                <div class="col-md-2 ">
                    <div class="filter-box-area" id="phaseContainer"><p class="filter-box-title">PHASE</p><p><input type="checkbox" checked="" id="PHall" name="PHall"><label for="PHall"> All</label></p><p><input type="checkbox" id="PH1" name="PH1"><label for="PH1"> 1</label></p><p><input type="checkbox" id="PH2" name="PH2"><label for="PH2"> 2</label></p><p><input type="checkbox" id="PH3" name="PH3"><label for="PH3"> 3</label></p></div>
                </div>
                <div class="col-md-2 ">
                    <div class="filter-box-area">
                        <a class="filter-reset-title" data-click-type="promo" data-click-text="Reset All Filters" style="display: none;">
                            
                            <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/filter-result-close-icon.svg?la=en&amp;hash=1EC02CA1569529AE25C879BC0C72DFB8" class="icon-close lozad" alt="icon-close">
                            <span>Reset All Filters</span>
                        </a>
                    </div>
                </div>
                <div class="col-md-2 ">
                    <button type="button" class="apply-filter" data-click-type="promo" data-click-text="APPLY FILTERS">
                        <span>APPLY FILTERS</span>
                    </button>
                </div>
            </div>
        </div>
    </div>
</div>
<!--Filter Facets-->
<!--No Results-->
<div class="collapseContainer">
    <div class=" container">
        <div class="row filter-result-container" style="display: none;">
            <div class="col-md-2 filter-result-count">
                <p class="rs-filters d-none">Showing <span class="filterCount">38</span> result<span class="rs-multiple">s</span> <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/filter-result-arrow.svg" class="result-arrow-icon" alt="Filter Close Icon"> </p>
<p class="rs-search">
            </p></div>
            <div class="col-md-8 selectedFilterList">
            </div>
            <div class="col-md-2 filterResultReset" style="display: none;">
                <!-- <a href="#" class="filter-result-reset"><span class="Icon-Close-test">s</span> -->
                <!-- <span>Reset all filters</span> -->
                <!-- </a> -->
                <a href="#" class="filter-result-reset" data-click-type="promo" data-click-text="Clear Filters">
                    <span class="filterClearIcon"></span>
                    <span class="rs-filters">
<img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/clear-filter-close-icon.svg" class="result-close-icon" alt="clear Filter Icon">
Clear Filters 
</span>
<span class="rs-search d-none">
<img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/clear-filter-close-icon.svg" class="result-close-icon" alt="clear Filter Icon">
Clear Search 
</span>
 
 

                </a>
            </div>
        </div>
        <div class="moleculeListContainer">
            <div class="row moleculeTitle">
                <div class="col-sm-3 p-pad-0">
                    <div class="textContentTitle">
                        <p>MOLECULE NAME</p>
                    </div>
                </div>
                <div class="col-sm-9 p-pad-0">
                    <div class="wrapper row">
                        <div class="col-sm-4">
                            <div class="card card-block"> THERAPEUTIC AREA</div>
                        </div>
                        <div class="col-sm-4">
                            <div class="card card-block">Investigational Indication</div>
                        </div>
                        <div class="col-sm-3">
                            <div class="card card-block">MODALITY</div>
                        </div>
                        <div class="col-sm-1">
                            <div class="card card-block">PHASE</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="molecule-list-container desktop-view"><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Aimovig<sup>®</sup><br> <span>(erenumab-aooe)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Neuroscience</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Migraine </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Aimovig is developed in partnership with Novartis.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/Aimovig/Aimovig_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMJEVITA™<br> <span>(adalimumab-atto)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Interchangeability </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMJEVITA (adalimumab-atto) is a biosimilar to HUMIRA<sup>®</sup> (adalimumab), which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">HUMIRA is a registered trademark of AbbVie Biotechnology Ltd.
AMJEVITA is a trademark of Amgen Inc.</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/AMJEVITA/AMJEVITA_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>BEMARITUZUMAB<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Gastric and Gastroesophageal Junction (GEJ) Cancers </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric and Gastroesophageal Junction (GEJ) Cancers. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for bemarituzumab.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Non-Small Cell Lung Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced squamous non-small cell lung cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Other Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced solid tumors other than advanced squamous non-small cell lung cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>BLINCYTO<sup>®</sup><br> <span>(blinatumomab)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Acute Lymphoblastic Leukemia </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in newly diagnosed adults age 40 and older with Ph negative B-Cell precursor Acute Lymphoblastic Leukemia (ALL). </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>EVENITY<sup>®</sup>

<br> <span>(romosozumab-aqqg)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Bone</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Male Osteoporosis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> EVENITY&nbsp;is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of&nbsp;&nbsp;male osteoporosis. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">EVENITY<sup></sup>is being developed in collaboration with UCB.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/evenity/evenity_pi_hcp_english.pdf" target="" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Bone</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Osteogenesis Imperfecta </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">EVENITY is being developed in collaboration with UCB.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/evenity/evenity_pi_hcp_english.pdf" target="" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>KYPROLIS<sup>®</sup><br> <span>(carfilzomib)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Multiple Myeloma </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combination with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"><label class="innerContentTitle">PRONUNCIATION</label> <p> /car fil' zoe mib /<audio id="myAudio"><source src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/pronunciation/kyprolis-carfilzomib.mp3" type="audio/mpeg"></audio><span class="audioIcon"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/audio.svg"></span></p> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Acute Lymphoblastic Leukemia </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"><label class="innerContentTitle">PRONUNCIATION</label> <p> /car fil' zoe mib /<audio id="myAudio"><source src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/pronunciation/kyprolis-carfilzomib.mp3" type="audio/mpeg"></audio><span class="audioIcon"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/audio.svg"></span></p> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>LUMAKRAS<sup>™</sup><br><span style="text-transform: lowercase !important;">(sotorasib)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Advanced Colorectal Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> LUMAKRAS is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced colorectal cancer. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC as monotherapy and in combination with other therapies.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/lumakras/lumakras_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Non-Small Cell Lung Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> LUMAKRAS (sotorasib) is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing authorization has subsequently been granted in the European Union as well as in additional countries, including some under FDA’s Project Orbis initiative, such as Canada and U.K. Additional marketing applications are also under review.</p>

<label class="innerContentTitle">ADDITIONAL CLINICAL STUDIES</label>
<p class="innterContentText">LUMAKRAS is also in Phase 1 and Phase 2 development for the treatment of NSCLC as monotherapy and in combination with other therapies.</p>
<p></p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/lumakras/lumakras_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Other Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> LUMAKRAS is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC as monotherapy and in combination with other therapies.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/lumakras/lumakras_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Nplate<sup>®</sup><br> <span>(romiplostim)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Chemotherapy-Induced Thrombocytopenia </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Peptibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Nplate<sup>&nbsp;</sup>is a thrombopoietin receptor agonist (TPO-RA).  It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT). </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Otezla<sup>®</sup><br> <span>(apremilast)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Plaque Psoriasis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe&nbsp;plaque psoriasis in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Genital Psoriasis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe genital psoriasis. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Juvenile Psoriatic Arthritis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Behcet’s Disease </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet’s in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Palmoplantar Pustulosis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of palmoplantar pustulosis. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Parsabiv<sup>®</sup><br> <span>(etelcalcetide)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Nephrology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Secondary Hyperparathyroidism </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Peptide</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Parsabiv is a calcium-sensing receptor agonist.  It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/parsabiv/parsabiv_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Prolia<sup>®</sup>
<br> <span>(denosumab)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Bone</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Glucocorticoid-Induced Osteoporosis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/prolia/prolia_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Bone</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Pediatric Osteogenesis Imperfecta </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Prolia is a monoclonal antibody that inhibits RANK ligand.  It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/prolia/prolia_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Repatha<sup>®</sup><br> <span>(evolocumab)</span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Cardiometabolic</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Hypercholesterolemia </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Rocatinlimab<br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG 451 / KHK4083</span>)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Atopic Dermatitis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Rocatinlimab (formerly AMG 451/KHK4083) is an anti-OX40 monoclonal antibody that inhibits activated OX40 expressing T cells and reduces their number. It is being investigated for the treatment of moderate-to-severe atopic dermatitis. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">AMG 451 (KHK4083) is being developed in collaboration with Kyowa Kirin Co., Ltd.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>TEZSPIRE™ <br><span style="text-transform: lowercase !important;">(tezepelumab-ekko)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Asthma </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of severe asthma. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Following a priority review by the U.S. FDA, Tezspire was approved in December 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Regulatory reviews are underway in the EU, Japan, and other jurisdictions<br><br>
Tezspire is being developed in collaboration with AstraZeneca plc.
</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Chronic Rhinosinusitis with Nasal Polyps </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Tezspire is being developed in collaboration with AstraZeneca plc.</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Chronic Obstructive Pulmonary Disease </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD). </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Tezspire is being developed in collaboration with AstraZeneca plc.</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Chronic Spontaneous Urticaria </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic spontaneous urticaria (CSU). </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Tezspire is being developed in collaboration with AstraZeneca plc.
</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>ABP 654<br> <span><span style="text-transform: none">(Investigational biosimilar to STELARA<sup>®</sup><br>
(ustekinumab))
</span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Investigational Biosimilar </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> ABP 654 is an investigational biosimilar to STELARA (ustekinumab), which is a monoclonal antibody that inhibits IL-12 and IL-23. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">STELARA is a registered trademark of Johnson &amp; Johnson.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>ABP 938<br> <span><span style="text-transform: none">(Investigational biosimilar to EYLEA<sup>®</sup><br>
(aflibercept))</span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Investigational Biosimilar </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Fusion Protein</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> ABP 938 is an investigational biosimilar to EYLEA (aflibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.

 </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText"> EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>ABP 959<br> <span><span style="text-transform: none">(Investigational biosimilar to Soliris<sup>®</sup><br>
(eculizumab))</span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Investigational Biosimilar </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> ABP 959 is an investigational biosimilar to SOLIRIS (eculizumab), which is a monoclonal antibody that specifically binds to the complement protein C5. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">SOLIRIS is a registered trademark of Alexion Pharmaceuticals Inc.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Efavaleukin alfa <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 592)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Systemic Lupus Erythematosus </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Fusion Protein</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Ulcerative Colitis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Fusion Protein</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of ulcerative colitis. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>OLPASIRAN<br>
<span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 890)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Cardiometabolic</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Cardiovascular Disease </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">siRNA</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Olpasiran (formerly AMG 890)  is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>ORDESEKIMAB<br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG 714 / PRV-015</span>)</span>
<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Celiac Disease </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Ordesekimab (formerly AMG 714/PRV-015) is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of non-responsive celiac disease as an adjunct to a gluten free diet. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Ordesekimab is being developed in collaboration with Provention Bio.&nbsp;</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>Rozibafusp alfa <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 570)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Systemic Lupus Erythematosus </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Antibody-Peptide Conjugate</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Rozibafusp alfa (formerly AMG 570) is a novel antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity. It is being investigated for the treatment of systemic lupus erythematosus. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>TARLATAMAB  <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 757)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Small-Cell Lung Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small-cell lung cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Neuroendocrine Prostate Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>ACAPATAMAB <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 160)</span><br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Prostate Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of prostate cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Non-Small Cell Lung Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC). </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 104<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Inflammation</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Asthma </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 104 is a human anti-TSLP Fab. It is being investigated for the treatment of asthma. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">AMG 104 is being developed in collaboration with AstraZeneca plc.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 119<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Small-Cell Lung Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">CAR T</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 119 is a delta-like ligand 3 (DLL3) chimeric antigen receptor T cell (CAR T) cellular therapy. It is being investigated for the treatment of small-cell lung cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 133<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Cardiometabolic</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Obesity </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Antibody-Peptide Conjugate&nbsp;</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 176<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Hematology </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1).&nbsp; It is being investigated for the treatment of hematologic malignancies. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 193<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Solid Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 199<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Solid Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of MUC17-Positive Solid Tumors including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 256<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Solid Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Bifunctional Fusion Protein</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 340<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Prostate Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 340 (previously TNB 585) is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 lower T cell affinity bispecific T cell engager (BiTE) molecule and is designed using the human heavy chain antibody platform. It is being investigated for the treatment of prostate cancer. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 404<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Solid Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Monoclonal Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 404 is an anti-programmed cell death-1(PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 427<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Acute Myeloid Leukemia </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">BiTE<sup>®</sup> Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 509<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Prostate Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">XmAb<sup>®</sup> Antibody</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 509 (STEAP1 XmAb antibody) is a bivalent Tcell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer. 
 </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">XmAb is a registered trademark of Xencor, Inc.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 609<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Metabolic Disorders</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Nonalcoholic Steatohepatitis </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">siRNA small molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 609 is a small interfering RNA (siRNA) that selectively targets a variant allele of patatin like phospholipase domain containing 3, also known as PNPLA3 I148M. It is being investigated for the treatment of nonalcoholic steatohepatitis (NASH).
 </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 650<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Solid Tumors </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 650 is a small molecule KIF18A inhibitor. It is being investigated as a treatment for advanced solid tumors. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 651<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Hematology / Oncology</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Colorectal Cancer </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Bispecific T-Cell Engager</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 651 (CX-904) is a T-cell engaging bispecific Probody<sup>®</sup> candidate against epidermal growth factor receptor (EGFR) and CD3. It is being investigated for the treatment of solid tumors. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">AMG 651 is being developed in collaboration with CytomX Therapeutics, Inc.</p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div><div class="row collapsibleContent"><div class="col-sm-3 border-right" style="padding:0px !important"><div class="textContent"><p>AMG 786<br> <span></span></p> </div> </div> <div class="col-sm-9" style="padding:0px !important"> <div class="wrapper row">  <div class="col-sm-4 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"><h4 class="panel-title"><a href="javascript:void(0)" data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span><span class="tarea-text">Cardiometabolic</span> </a> </h4> </div> </div>  </div>  <div class="col-sm-4 second-column"> <div class="card card-block"> <a href="javascript:void(0)">Obesity </a></div> </div> <div class="col-sm-3 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small Molecule</a></div> </div> <div class="col-sm-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span> </a>  </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-sm-8"> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 786 is a small molecule being investigated for the treatment of obesity. </p>  </div> <div class="col-sm-4 pronunce-content"> </div> </div> <p></p> </div> </div> </div></div>
            <div class="molecule-list-container mobile-view"> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Aimovig<sup>®</sup><br> <span>(erenumab-aooe)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Migraine</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Neuroscience </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Aimovig is developed in partnership with Novartis.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/Aimovig/Aimovig_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMJEVITA™<br> <span>(adalimumab-atto)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Interchangeability</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMJEVITA (adalimumab-atto) is a biosimilar to HUMIRA<sup>®</sup> (adalimumab), which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">HUMIRA is a registered trademark of AbbVie Biotechnology Ltd.
AMJEVITA is a trademark of Amgen Inc.</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/AMJEVITA/AMJEVITA_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>BEMARITUZUMAB<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Gastric and Gastroesophageal Junction (GEJ) Cancers</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric and Gastroesophageal Junction (GEJ) Cancers. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for bemarituzumab.</p>  </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Non-Small Cell Lung Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced squamous non-small cell lung cancer. </p>  </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Other Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced solid tumors other than advanced squamous non-small cell lung cancer. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>BLINCYTO<sup>®</sup><br> <span>(blinatumomab)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Acute Lymphoblastic Leukemia</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in newly diagnosed adults age 40 and older with Ph negative B-Cell precursor Acute Lymphoblastic Leukemia (ALL). </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/blincyto/blincyto_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>EVENITY<sup>®</sup>

<br> <span>(romosozumab-aqqg)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Male Osteoporosis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Bone </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> EVENITY&nbsp;is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of&nbsp;&nbsp;male osteoporosis. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">EVENITY<sup></sup>is being developed in collaboration with UCB.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/evenity/evenity_pi_hcp_english.pdf" target="" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Osteogenesis Imperfecta</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Bone </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">EVENITY is being developed in collaboration with UCB.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/evenity/evenity_pi_hcp_english.pdf" target="" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>KYPROLIS<sup>®</sup><br> <span>(carfilzomib)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Multiple Myeloma</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combination with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma. </p><label class="innerContentTitle">PRONUNCIATION</label> <p> /car fil' zoe mib /<audio id="myAudio"><source src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/pronunciation/kyprolis-carfilzomib.mp3" type="audio/mpeg"></audio><span class="audioIcon"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/audio.svg"></span></p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Acute Lymphoblastic Leukemia</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients. </p><label class="innerContentTitle">PRONUNCIATION</label> <p> /car fil' zoe mib /<audio id="myAudio"><source src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/pronunciation/kyprolis-carfilzomib.mp3" type="audio/mpeg"></audio><span class="audioIcon"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/audio.svg"></span></p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/kyprolis/kyprolis_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>LUMAKRAS<sup>™</sup><br><span style="text-transform: lowercase !important;">(sotorasib)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Advanced Colorectal Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> LUMAKRAS is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced colorectal cancer. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC as monotherapy and in combination with other therapies.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/lumakras/lumakras_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Non-Small Cell Lung Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> LUMAKRAS (sotorasib) is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing authorization has subsequently been granted in the European Union as well as in additional countries, including some under FDA’s Project Orbis initiative, such as Canada and U.K. Additional marketing applications are also under review.</p>

<label class="innerContentTitle">ADDITIONAL CLINICAL STUDIES</label>
<p class="innterContentText">LUMAKRAS is also in Phase 1 and Phase 2 development for the treatment of NSCLC as monotherapy and in combination with other therapies.</p>
<p></p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/lumakras/lumakras_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Other Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> LUMAKRAS is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC as monotherapy and in combination with other therapies.</p> <ul class="customBreadcrumb"> <li><a href="https://pi.amgen.com/united_states/lumakras/lumakras_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Nplate<sup>®</sup><br> <span>(romiplostim)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Chemotherapy-Induced Thrombocytopenia</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Peptibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Nplate<sup>&nbsp;</sup>is a thrombopoietin receptor agonist (TPO-RA).  It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT). </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/nplate/nplate_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Otezla<sup>®</sup><br> <span>(apremilast)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Plaque Psoriasis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe&nbsp;plaque psoriasis in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Genital Psoriasis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe genital psoriasis. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Juvenile Psoriatic Arthritis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Behcet’s Disease</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet’s in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Palmoplantar Pustulosis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of palmoplantar pustulosis. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Parsabiv<sup>®</sup><br> <span>(etelcalcetide)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Secondary Hyperparathyroidism</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Nephrology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Peptide </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Parsabiv is a calcium-sensing receptor agonist.  It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/parsabiv/parsabiv_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Prolia<sup>®</sup>
<br> <span>(denosumab)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Glucocorticoid-Induced Osteoporosis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Bone </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/prolia/prolia_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Pediatric Osteogenesis Imperfecta</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Bone </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Prolia is a monoclonal antibody that inhibits RANK ligand.  It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/prolia/prolia_pi.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Repatha<sup>®</sup><br> <span>(evolocumab)</span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Hypercholesterolemia</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Cardiometabolic </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke. </p><label class="innerContentTitle">ADDITIONAL INFORMATION</label> <ul class="customBreadcrumb"> <li><a href="http://pi.amgen.com/united_states/repatha/repatha_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information">Prescribing Information<img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Rocatinlimab<br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG 451 / KHK4083</span>)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Atopic Dermatitis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Rocatinlimab (formerly AMG 451/KHK4083) is an anti-OX40 monoclonal antibody that inhibits activated OX40 expressing T cells and reduces their number. It is being investigated for the treatment of moderate-to-severe atopic dermatitis. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">AMG 451 (KHK4083) is being developed in collaboration with Kyowa Kirin Co., Ltd.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>TEZSPIRE™ <br><span style="text-transform: lowercase !important;">(tezepelumab-ekko)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Asthma</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of severe asthma. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Following a priority review by the U.S. FDA, Tezspire was approved in December 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Regulatory reviews are underway in the EU, Japan, and other jurisdictions<br><br>
Tezspire is being developed in collaboration with AstraZeneca plc.
</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Chronic Rhinosinusitis with Nasal Polyps</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Tezspire is being developed in collaboration with AstraZeneca plc.</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Chronic Obstructive Pulmonary Disease</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD). </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Tezspire is being developed in collaboration with AstraZeneca plc.</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Chronic Spontaneous Urticaria</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tezspire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic spontaneous urticaria (CSU). </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Tezspire is being developed in collaboration with AstraZeneca plc.
</p> <ul class="customBreadcrumb"> <li><a href="https://www.pi.amgen.com/united_states/tezspire/tezspire_pi_hcp_english.pdf" target="_blank" data-click-type="outbound" data-click-text="Prescribing Information ">Prescribing Information <img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow-long.png"></a></li> </ul> </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>ABP 654<br> <span><span style="text-transform: none">(Investigational biosimilar to STELARA<sup>®</sup><br>
(ustekinumab))
</span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Biosimilar</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> ABP 654 is an investigational biosimilar to STELARA (ustekinumab), which is a monoclonal antibody that inhibits IL-12 and IL-23. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">STELARA is a registered trademark of Johnson &amp; Johnson.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>ABP 938<br> <span><span style="text-transform: none">(Investigational biosimilar to EYLEA<sup>®</sup><br>
(aflibercept))</span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Biosimilar</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Fusion Protein </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> ABP 938 is an investigational biosimilar to EYLEA (aflibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.

 </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText"> EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>ABP 959<br> <span><span style="text-transform: none">(Investigational biosimilar to Soliris<sup>®</sup><br>
(eculizumab))</span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Biosimilar</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH3 ">3</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> ABP 959 is an investigational biosimilar to SOLIRIS (eculizumab), which is a monoclonal antibody that specifically binds to the complement protein C5. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">SOLIRIS is a registered trademark of Alexion Pharmaceuticals Inc.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Efavaleukin alfa <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 592)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Systemic Lupus Erythematosus</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Fusion Protein </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus. </p>  </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Ulcerative Colitis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Fusion Protein </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of ulcerative colitis. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>OLPASIRAN<br>
<span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 890)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Cardiovascular Disease</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Cardiometabolic </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> siRNA </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Olpasiran (formerly AMG 890)  is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>ORDESEKIMAB<br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG 714 / PRV-015</span>)</span>
<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Celiac Disease</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Ordesekimab (formerly AMG 714/PRV-015) is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of non-responsive celiac disease as an adjunct to a gluten free diet. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">Ordesekimab is being developed in collaboration with Provention Bio.&nbsp;</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>Rozibafusp alfa <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 570)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Systemic Lupus Erythematosus</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Antibody-Peptide Conjugate </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Rozibafusp alfa (formerly AMG 570) is a novel antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity. It is being investigated for the treatment of systemic lupus erythematosus. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>TARLATAMAB  <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 757)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small-Cell Lung Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH2 ">2</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small-cell lung cancer. </p>  </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Neuroendocrine Prostate Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>ACAPATAMAB <br><span style="text-transform: lowercase !important;">(formerly <span style="text-transform: uppercase !important;">AMG</span> 160)</span><br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Prostate Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of prostate cancer. </p>  </div> </div> <p></p> </div> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Non-Small Cell Lung Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC). </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 104<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Asthma</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Inflammation </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 104 is a human anti-TSLP Fab. It is being investigated for the treatment of asthma. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">AMG 104 is being developed in collaboration with AstraZeneca plc.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 119<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Small-Cell Lung Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> CAR T </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 119 is a delta-like ligand 3 (DLL3) chimeric antigen receptor T cell (CAR T) cellular therapy. It is being investigated for the treatment of small-cell lung cancer. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 133<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Obesity</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Cardiometabolic </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Antibody-Peptide Conjugate&nbsp; </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 176<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Hematology</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1).&nbsp; It is being investigated for the treatment of hematologic malignancies. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 193<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Solid Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor. It is being investigated for the treatment of solid tumors. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 199<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Solid Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of MUC17-Positive Solid Tumors including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 256<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Solid Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Bifunctional Fusion Protein </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 340<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Prostate Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 340 (previously TNB 585) is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 lower T cell affinity bispecific T cell engager (BiTE) molecule and is designed using the human heavy chain antibody platform. It is being investigated for the treatment of prostate cancer. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 404<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Solid Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Monoclonal Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 404 is an anti-programmed cell death-1(PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 427<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Acute Myeloid Leukemia</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> BiTE<sup>®</sup> Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 509<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Prostate Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> XmAb<sup>®</sup> Antibody </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 509 (STEAP1 XmAb antibody) is a bivalent Tcell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer. 
 </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">XmAb is a registered trademark of Xencor, Inc.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 609<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Nonalcoholic Steatohepatitis</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Metabolic Disorders </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> siRNA small molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 609 is a small interfering RNA (siRNA) that selectively targets a variant allele of patatin like phospholipase domain containing 3, also known as PNPLA3 I148M. It is being investigated for the treatment of nonalcoholic steatohepatitis (NASH).
 </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 650<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Solid Tumors</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 650 is a small molecule KIF18A inhibitor. It is being investigated as a treatment for advanced solid tumors. </p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 651<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Colorectal Cancer</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Hematology / Oncology </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Bispecific T-Cell Engager </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 651 (CX-904) is a T-cell engaging bispecific Probody<sup>®</sup> candidate against epidermal growth factor receptor (EGFR) and CD3. It is being investigated for the treatment of solid tumors. </p> <label class="innerContentTitle">ADDITIONAL INFORMATION</label> <p class="innterContentText">AMG 651 is being developed in collaboration with CytomX Therapeutics, Inc.</p>  </div> </div> <p></p> </div> </div> </div> <div class="row collapsibleContent"> <div class="col-12 border-bottom"> <div class="textContent"> <p>AMG 786<br> <span></span></p></div>  </div> <div class="col-12"> <div class="wrapper row">  <div class="col-1 first-column"> <div class="panel panel-default"> <div class="panel-heading active" role="tab" id="headingOne"> <h4 class="panel-title"><a data-toggle="collapse"><span class="arrow"><img src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/accordian-arrow.png"></span> </a> </h4> </div> </div>  </div>  <div class="col-5 second-column"> <div class="card card-block"><a href="javascript:void(0)">Investigational Indication</a></div> </div> <div class="col-5 third-column"> <div class="card card-block"><a href="javascript:void(0)">Obesity</a></div> </div> <div class="col-1 fourth-column"><a href="javascript:void(0)"> <span class="badge phases-PH1 ">1</span></a> </div>  </div>  <div class="collapseData"> <div class="row"> <div class="col-12"> <label class="innerContentTitle">THERAPEUTIC AREA</label> <p class="innterContentText"> Cardiometabolic </p> <label class="innerContentTitle">MODALITY</label> <p class="innterContentText"> Small Molecule </p> <label class="innerContentTitle">DESCRIPTION</label> <p class="innterContentText"> AMG 786 is a small molecule being investigated for the treatment of obesity. </p>  </div> </div> <p></p> </div> </div> </div></div>
        </div>
        <div class="row noMoleculeResultContainer" style="display: none;">
            <div class="col-md-5 noResult">
            <p><img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/filter-result-warning-icon.svg" class="result-warning-icon" alt="Warning Icon">No molecules match your criteria</p>
        </div>
        <div class="col-md-7 text-left">
            <button class="btn btnViewAllMolecules">VIEW ALL MOLECULES</button>
        </div>
        </div>
    </div>
</div>

    
    



    <div class="quantum-container--primary quantum-back-to-top  quantum-back-to-top--persistent " id="" style="display: none;">
        <div class="quantum-back-to-top__inner">
            <a class="quantum-back-to-top__target " href="#">


                    <span class="quantum-back-to-top__label">
                        
                        <svg class="quantum-icon quantum-back-to-top__static-icon">

                            <use xlink:href="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow_svg.svg#"></use>

                        </svg>
                    </span>
                    <span class="quantum-back-to-top__button quantum-button quantum-button--icon-only" title="Back to Top"><img class="btarrow-img" src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow_svg.svg">
                        <svg class="quantum-icon quantum-button__icon">
                            <use xlink:href="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/arrow_svg.svg#"></use>

                        </svg>
                    </span>
            </a>
        </div>
    </div><iframe name="__uspapiLocator" tabindex="-1" role="presentation" aria-hidden="true" title="Blank" style="display: none; position: absolute; width: 1px; height: 1px; top: -9999px;"></iframe>




    <footer id="footer">
        



<div class="component container" id="footer-quick-links">
    <div class="component-content">


    <div class="component rich-text col-12">
        <div class="component-content">
Quick Links        </div>
    </div>

<div class="quantum-quicklinks " id="">
    <div class="quantum-quicklinks__inner">

                <div class="quantum-quicklinks__column">

                    <ul class="quantum-list-group quantum-quicklinks__column-list-group quantum-list-group--small">
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Investors" href="http://investors.amgen.com/" target="">Investors</a>

                                </li>
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Amgen Medical Information" href="https://www.amgenmedinfo.com/" target="">Amgen Medical Information</a>

                                </li>
                        


                    </ul>
                </div>
                <div class="quantum-quicklinks__column">

                    <ul class="quantum-list-group quantum-quicklinks__column-list-group quantum-list-group--small">
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Amgen Media Relations" href="https://www.amgen.com/media/" target="">Amgen Media Relations</a>

                                </li>
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Contact us" href="https://www.amgen.com/contact-us/" target="">Contact Us</a>

                                </li>
                        


                    </ul>
                </div>
                <div class="quantum-quicklinks__column">

                    <ul class="quantum-list-group quantum-quicklinks__column-list-group quantum-list-group--small">
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Amgen Biosimilars" href="https://www.amgenbiosimilars.com/" target="">AmgenBiosimilars.com</a>

                                </li>
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Amgen" href="https://www.amgen.com/" target="">Amgen.com</a>

                                </li>
                        


                    </ul>
                </div>
                <div class="quantum-quicklinks__column">

                    <ul class="quantum-list-group quantum-quicklinks__column-list-group quantum-list-group--small">
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Amgen Science" href="https://www.amgenscience.com/" target="">AmgenScience.com</a>

                                </li>
                                <li class="quantum-list-group__item ">


                                    <a class="quantum-list-group__link  " data-click-type="outbound" data-click-text="Amgen Trails" href="http://www.amgentrials.com/amgen/study.aspx" target="">Amgentrials.com</a>

                                </li>
                        


                    </ul>
                </div>

    </div>
</div>



    </div>
</div>



<div class="component container" id="disclaimer-info">
    <div class="component-content">



<div class="component row-splitter">
        <div class="container-fluid">
            <div>
                

    <div class="component rich-text col-12">
        <div class="component-content">
<p>*&nbsp;&nbsp;Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.</p>
<p>‡&nbsp;&nbsp;In addition to the above programs, AMJEVITA<sup>®</sup>/AMGEVITA<sup>®</sup>,  MVASI<sup>®</sup>, KANJINTI<sup>®</sup>, and RIABNI™ have been  approved by the United States Food and Drug Administration (FDA) and the  European &nbsp;Commission (EC). AVSOLA<sup>®</sup> has been approved by the FDA</p>        </div>
    </div>

            </div>
        </div>
        <div class="container-fluid">
            <div>
                

    <div class="component rich-text col-12">
        <div class="component-content">
<p>This pipeline presents a selection of the Company’s product candidates and is designed to demonstrate the range of the Company’s commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of August 4, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.&nbsp; </p>        </div>
    </div>

            </div>
        </div>
</div>    </div>
</div>


    <div class="quantum-container--secondary quantum-footer " id="">
        <div class="quantum-footer__inner">

            


    <div class="quantum-footer__logo-social-row">


            <a title="Logo" href="/" target="" class=" quantum-footer__logo-link ">
                <svg class="quantum-icon">
                    </svg><img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/amgen-logo.svg?h=36&amp;w=151&amp;la=en&amp;hash=047A41224BAD77E1DD4DA6252B9E441C" class="d-none d-sm-block quantum-footer__quantum-logo lozad" alt="footer logo">
                    <img src="-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/images/Common/amgen-logo.svg?h=36&amp;w=151&amp;la=en&amp;hash=047A41224BAD77E1DD4DA6252B9E441C" class="d-block d-sm-none quantum-footer__quantum-logo lozad" alt="footer logo">
                

            </a>



    </div>


            

            
<div class="quantum-footer__links-row">


                    <a href="https://wwwext.amgen.com/terms-of-use/" class="  gtm-footerCl quantum-link quantum-footer__link" menu-name="terms of use" menu-type="footer" data-click-type="outbound" data-click-text="terms of use" target="">
                      Terms of Use
                    </a>
                    <a href="https://wwwext.amgen.com/privacy-statement/" class="  gtm-footerCl quantum-link quantum-footer__link" menu-name="privacy statement" menu-type="footer" data-click-type="outbound" data-click-text="privacy statement" target="">
                      Privacy Statement
                    </a>
</div>
            
            <p class="quantum-footer__legal-row">
                © 2022 Amgen Inc. All Rights Reserved.
            </p>

        </div>
    </div>




            <script>
                var doPopup = "True";
            </script>
    </footer>
    

<script src="/-/media/Base-Themes/Core-Libraries/scripts/ie-origin-fix.js"></script><iframe tabindex="-1" role="presentation" aria-hidden="true" title="Blank" style="position: absolute; width: 1px; height: 1px; top: -9999px;" src="https://consentcdn.cookiebot.com/sdk/bc-v4.min.html"></iframe><script src="/-/media/Base-Themes/Core-Libraries/scripts/xaquery.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/moment.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/lo-dash.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/modernizr.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/galleria-161.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/fullcalendar.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/gcal.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/jqueryuitouch-punchmin.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/hammer.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/backbone-min.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/typeahead.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/jquerymCustomScrollbar.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/flash-polyfill.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/mediaelement-and-player.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/dailymotion.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/facebook.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/soundcloud.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/twitch.js"></script><script src="/-/media/Base-Themes/Core-Libraries/scripts/vimeo.js"></script><script src="/-/media/Base-Themes/XA-API/Scripts/xa.js"></script><script src="/-/media/Base-Themes/Main-Theme/scripts/observer.js"></script><script src="/-/media/Base-Themes/Main-Theme/scripts/partial-design-highlight.js"></script><script src="/-/media/Base-Themes/NG-Amgen-Query-String-Handler/Scripts/QueryStringProcessor.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/accessibility.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-accordions.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-archive.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-breadcrumb.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-carousel.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-container.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-disqus.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-facebook.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-flash.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-flip.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-fullcalendar.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-galleria.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-language-selector.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-navigation.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-overlay.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-snippet.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-social.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-tabs.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-toggle.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-video.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/component-video-playlist.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/details-polyfill.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/fixheight.js"></script><script src="/-/media/Base-Themes/Components-Theme/Scripts/search-fixheight.js"></script><script src="/-/media/Base-Themes/Resolve-Conflicts/Scripts/resolveconflicts.js"></script><script src="/-/media/Base-Themes/NG-Amgen-Google-Tag-Manager/Scripts/AccordinGtmTracking.js"></script><script src="/-/media/Base-Themes/NG-Amgen-Google-Tag-Manager/Scripts/BrightCoverVideoGTMTracking.js"></script><script src="/-/media/Base-Themes/NG-Amgen-Google-Tag-Manager/Scripts/GTMinlineScript.js"></script><script src="/-/media/Base-Themes/NG-Amgen-Google-Tag-Manager/Scripts/GTMinlineScriptCL.js"></script><script src="/-/media/Base-Themes/NG-Amgen-Google-Tag-Manager/Scripts/trackGTM.js"></script><script src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/Scripts/Gtm.js"></script><script src="/-/media/Themes/Amgen/amgenpipeline-com/amgenpipeline-com/Scripts/pipeline-custom.js"></script>
    
    



</body></html>